H.I.G. BioHealth Partners -

H.I.G. Capital News / Earlier

December 18, 2018 - Apollo Endosurgery, Inc. Announces the Sale of Its Surgical Product Line

AUSTIN, TX - December 18, 2018 - Apollo Endosurgery, Inc. (“Apollo”) (Nasdaq:APEN), a global leader in less invasive medical devices for bariatric and gastrointestinal procedures, today announced the sale of its Surgical product line, which consists of the Lap-Band® adjustable…
November 29, 2018 - CardioFocus Completes Enrollment In HeartLight® X3 Trial

MARLBOROUGH, MA – November 29, 2018 - CardioFocus, Inc., a medical device company dedicated to advancing ablation treatment for atrial fibrillation (AFib), today announced completed enrollment in a trial to evaluate its next-generation HeartLight® X3 Endoscopic Ablation System. A…
November 27, 2018 - Apollo Endosurgery Announces First Commercial Shipment of the OverStitch™ Sx Endoscopic Suturing System

AUSTIN, TX - November 27, 2018 - Apollo Endosurgery, Inc. (“Apollo”) (Nasdaq:APEN), a global leader in less invasive medical devices for bariatric and gastrointestinal procedures, announced today the first commercial shipments of the OverStitch™ Sx Endoscopic Suturing System.…
November 20, 2018 - Vertiflex Announces Publication of Data Analysis Showing 85% Reduction in Patients Using Opioids After Treatment with Superion Indirect Decompression System

CARLSBAD, CA. - November 20, 2018 - Vertiflex® Inc., a leading innovator of advanced, minimally invasive interventions for spinal stenosis, announced additional results from a randomized, controlled trial of its Superion® Indirect Decompression System in patients with lumbar spinal…
November 6, 2018 - Intact Vascular Announces Positive One-Year Data from the TOBA II Clinical Trial

WAYNE, PA - November 6, 2018 – Intact Vascular, Inc., a developer of medical devices for minimally invasive peripheral vascular procedures, today announced at the 15th annual VIVA conference in Las Vegas that its Tack Optimized Balloon Angioplasty II (TOBA II) clinical trial successfully…
November 5, 2018 - Intact Vascular Hires Industry Veteran Steve MacKinnon as Vice President of Sales

WAYNE, PA - November 5, 2018 – Intact Vascular, Inc., a developer of medical devices for minimally invasive peripheral vascular procedures, today announced that Steve MacKinnon has joined its senior management team as Vice President of Sales, effective immediately. Reporting to the…
October 15, 2018 - On Target Laboratories Announces Publication Supporting Use of OTL78 to Highlight Prostate Cancer Lesions

WEST LAFAYETTE, IN - October 15, 2018 - On Target Laboratories, Inc., a privately held biotechnology company that is developing tumor-targeted fluorescent dyes to improve cancer surgery, announced today the publication of a study evaluating the effectiveness of On Target Laboratories'…
October 11, 2018 - H.I.G. BioHealth Partners Completes Sale of HyperBranch Medical Technology, Inc. to Stryker

MIAMI – October 11, 2018 - H.I.G. BioHealth Partners (“H.I.G.”), the dedicated healthcare investment affiliate of H.I.G. Capital, a leading global private equity investment firm with over $27 billion of equity capital under management,* recently announced the sale of HyperBranch…
August 6, 2018 - Symposium to Explore the Impact of Vascular Dissections on Critical Limb Ischemia Patients at AMP 2018

WAYNE, PA – August 6 , 2018 - Intact Vascular, Inc., a developer of medical devices for minimally invasive peripheral vascular procedures, today announced key presentations that will be featured during a CME symposium at the Amputation Prevention (AMP) Conference in Chicago on August…
July 11, 2018 - CardioFocus® Announces Full Commercial Launch of HeartLight® System in Japan

MARLBOROUGH, MA – July 11, 2018 - CardioFocus, Inc., a medical device innovator and manufacturer dedicated to advancing ablation treatment for atrial fibrillation (AF), today announced the commercial launch of its HeartLight Endoscopic Ablation System in Japan. The commercial launch…
July 11, 2018 - Intact Vascular Welcomes Publication of iDissection Classification Study Results in Journal of Invasive Cardiology

WAYNE, PA – July 11 , 2018 - Intact Vascular, Inc., a developer of medical devices for minimally invasive peripheral vascular procedures, today welcomed the publication of the iDissection Classification trial results in the current issue of Journal of Invasive Cardiology. Post-percutaneous…
June 11, 2018 - HyperBranch Medical Technology, Inc. Wins Jury Trial in Patent Infringement Lawsuit Filed by Integra LifeSciences

DURHAM, NC - June 11, 2018 - HyperBranch Medical Technology, Inc. announced today that on June 8, 2018, after a two-week trial in federal district court in Wilmington, Delaware, an 8-member jury found in favor of HyperBranch on all remaining claims and legal defenses at issue in a patent…
May 8, 2018 - Apollo Endosurgery Establishes European Registry for Bariatric Flexible Endoscopic Suturing Procedures

AUSTIN – May 8, 2018 - Apollo Endosurgery, Inc. (“Apollo”) (Nasdaq:APEN), a global leader in less invasive medical devices for bariatric and gastrointestinal procedures, announced today the establishment of a multicenter, longitudinal, data repository for Endoscopic Sleeve Gastroplasty…
May 7, 2018 - CardioFocus® Announces FDA Approval of the Next-Generation HeartLight® Excalibur Balloon™ Designed for the Treatment of Paroxysmal Atrial Fibrillation*

MARLBOROUGH, MA – May 7, 2018 - CardioFocus, Inc., today announced that the U.S. Food and Drug Administration (FDA) has granted approval for the HeartLight Excalibur Balloon, a next-generation technology designed for the treatment of paroxysmal atrial fibrillation (PAF)*. The Excalibur…
April 23, 2018 - Apollo Endosurgery Announces Approval of the New 12-month Weight Loss Balloon - ORBERA365™ - in the Kingdom of Saudi Arabia

AUSTIN - April 23, 2018 - Apollo Endosurgery, Inc. (“Apollo”) (Nasdaq:APEN), a global leader in less invasive medical devices for bariatric and gastrointestinal procedures, today announced that the Saudi Food and Drug Authority (SFDA) has approved the ORBERA365™ Managed Weight…
April 16, 2018 - Intact Vascular Announces $20 Million Series C Financing to Fund Company through PMA Approval of the Tack Endovascular System®

WAYNE, PA – April 16, 2018 - Intact Vascular, Inc., a developer of medical devices for minimally invasive peripheral vascular procedures, today announced that it closed a Series C financing totaling $20 million. This financing is designed to fund the Company through Pre-Market Approval…
April 16, 2018 - Intact Vascular Announces Enrollment Completion of the Tack Optimized Balloon Angioplasty III (TOBA III) Clinical Trial

WAYNE, PA – April 16, 2018 - Intact Vascular, Inc., a developer of medical devices for minimally invasive peripheral vascular procedures, today announced that its Tack Optimized…
April 5, 2018 - First Patient Treated in Pivotal Phase 3 Trial to Evaluate OTL38 in the Detection of Ovarian Cancer

WEST LAFAYETTE, IN - April 5, 2018 – On Target Laboratories, Inc., a privately held biotechnology company that is developing tumor-targeted fluorescent dyes to improve cancer surgery, announced today that the first patient was treated in a Phase 3 clinical trial of OTL38 in the detection…
March 27, 2018 - Intact Vascular Welcomes TOBA BTK Trial One-Year Clinical Study Results Publication in Catheterization and Cardiovascular Intervention

WAYNE, PA – March 27, 2018 - Intact Vascular, Inc., a developer of medical devices for minimally invasive peripheral vascular procedures, today welcomed the publication of the Tack Optimized Balloon Angioplasty Below the Knee (TOBA BTK) clinical trial results in the current issue…
March 14, 2018 - On Target Laboratories Raises Additional Capital from H.I.G. BioHealth Partners, Elevate Ventures and Helsinn

WEST LAFAYETTE, IN - March 14, 2018 – On Target Laboratories, Inc., a privately held biotechnology company that is developing tumor-targeted fluorescent dyes to improve cancer surgery, has secured an additional financing as part of its Series B capital raise which initially closed…
February 26, 2018 - CardioFocus Announces Initiation of HeartLight® X3 Clinical Evaluation

MARLBOROUGH, MA – February 26, 2018 - CardioFocus, Inc., a medical device innovator and manufacturer dedicated to advancing ablation treatment for cardiac disorders such as atrial fibrillation (AF), today announced the initiation of a clinical evaluation of the new HeartLight X3 System…
January 25, 2018 - TOBA II BTK Trial Enrollment Ahead of Schedule for the Tack Endovascular System® in Below the Knee Disease.

WAYNE, PA – January 25, 2018 - Intact Vascular, Inc., a developer of medical devices for minimally invasive peripheral vascular procedures, today announced the Tack Optimized…
January 9, 2018 - CardioFocus® Announces Expanded Partnership with Japan Lifeline

MARLBOROUGH, MA – January 9, 2018 - CardioFocus, Inc., a medical device innovator and manufacturer dedicated to advancing ablation treatment for cardiac disorders such as atrial fibrillation (AF), today announced that it has entered into an expanded partnership with Japan Lifeline…
November 29, 2017 - CardioFocus® Completes Successful Controlled U.S. Commercial Launch of the HeartLight® System

MARLBOROUGH, MA - November 29, 2017 - CardioFocus, Inc. today announced the successful completion of its controlled U.S. commercial launch of the HeartLight® Endoscopic Ablation System for the treatment of paroxysmal atrial fibrillation (AF). Ten leading cardiac centers across the…
November 27, 2017 - Apollo Endosurgery Receives FDA Clearance for OverStitch™ Sx Endoscopic Suturing System

AUSTIN - November 27, 2017 - Apollo Endosurgery, Inc. (“Apollo”) (NASDAQ:APEN), a leader in less invasive surgical medical devices for bariatric and gastrointestinal procedures, announced today U.S. Food and Drug Administration 510k clearance of the OverStitch Sx, a new, full-thickness…
November 22, 2017 - FDA Approves RxSight’s Light Adjustable Lens, First IOL to Enable Refractive Correction After Cataract Surgery

ALISO VIEJO, CA - November 22, 2017 - RxSight, Inc. announced today that the U.S. Food and Drug Administration (FDA) has approved the RxSight™ Light Adjustable Lens and the Light Delivery Device (LDD) for patients with pre-existing astigmatism of ≥ 0.75 diopters undergoing cataract…
November 16, 2017 - David C. Pacitti Joins Apollo Endosurgery Board of Directors

AUSTIN - November 16, 2017 - The Board of Directors of Apollo Endosurgery, Inc. (“Apollo”) (NASDAQ:APEN), today announced the appointment of David C. Pacitti as an independent director of Apollo. He will commence service on December 8, 2017. Mr. Pacitti’s appointment expands the…
September 27, 2017 - CardioFocus® Announces European CE Mark Approval of the Next-Generation HeartLight® Excalibur Balloon™ Designed for the Treatment of Atrial Fibrillation

MARLBOROUGH, MA – September 27, 2017 - CardioFocus, Inc. today announced the European CE Mark approval of the HeartLight Excalibur Balloon, a next-generation technology designed for the treatment of atrial fibrillation (AF). The Excalibur Balloon leverages the proven universal balloon…
August 31, 2017 - Apollo Endosurgery Announces 20-year LAP-BAND® Outcomes Data Presented at 22nd IFSO World Congress in London

AUSTIN - August 31, 2017 - Apollo Endosurgery, Inc. (NASDAQ:APEN), a leader in less invasive surgical medical devices for bariatric and gastrointestinal procedures, announced the presentation of 20 year outcomes data for the LAP-BAND® System today at the 22nd World Congress of the…
August 22, 2017 - Iconic Therapeutics Appoints Brandon Smith Chief Operating Officer

SAN FRANCISCO - August 22, 2017 – Iconic Therapeutics, a clinical stage biopharmaceutical company dedicated to translating knowledge of Tissue Factor biology into new therapeutics for retinal disease and cancer, announced the appointment of Brandon Smith as Chief Operating Officer.…
July 31, 2017 - CardioFocus® Receives Approval for HeartLight® Endoscopic Ablation System from the Japanese Ministry of Health, Labour and Welfare

MARLBOROUGH, MA - July 31, 2017 - CardioFocus, Inc. today announced that the Japanese Ministry of Health, Labour and Welfare has approved the HeartLight Endoscopic Ablation System for the treatment of paroxysmal atrial fibrillation (AF) in Japan. The HeartLight System is a visually…
July 20, 2017 - Apollo Endosurgery, Inc. Announces Pricing of $31 Million Public Offering

AUSTIN - July 20, 2017 - Apollo Endosurgery, Inc. (NASDAQ: APEN), a medical technology company primarily focused on the design, development and commercialization of innovative medical devices that can be used for the treatment of obesity, today announced the pricing of an underwritten…
July 18, 2017 - Intact Vascular Announces Enrollment of First European Patient in Tack Optimized Balloon Angioplasty II below the Knee (TOBA II BTK) Clinical Trial with the Tack Endovascular System ®

WAYNE, PA - July 18, 2017 - Intact Vascular, Inc., a developer of medical devices for minimally invasive peripheral vascular procedures, today announced that its Tack Optimized…
July 13, 2017 - Vertiflex, Inc. Appoints Michael Enxing to Vice President, Chief Commercial Officer

CARLSBAD, CA – July 13, 2017 – Vertiflex, Inc., a leading innovator of advanced, minimally invasive interventions for spinal stenosis, today announced the appointment of Michael Enxing as Vice President and Chief Commercial Officer. Mr. Enxing will be responsible for leading all…
July 10, 2017 - FDA Approves 6-month Primary Endpoint for the Tack Endovascular System® in below the Knee Disease

WAYNE, PA - July 10, 2017 - Intact Vascular, Inc., a developer of medical devices for minimally invasive peripheral vascular procedures, today announced the U.S. Food and Drug Administration (FDA) approved an Investigational Device Exemption (IDE) supplemental application to modify…
June 29, 2017 - CardioFocus® Announces Initiation of Three Major Studies Featuring the HeartLight® System for the Treatment of Atrial Fibrillation

MARLBOROUGH, MA - June 29, 2017 - CardioFocus, Inc., a medical device innovator and manufacturer dedicated to advancing ablation treatment for cardiac disorders such as atrial fibrillation (AF), today announced that its HeartLight Endoscopic Ablation System is being featured in three…
June 26, 2017 - Clarus Re-submits Jatenzo NDA Following Positive Results of Intune Trial

NORTHBROOK, IL – June 26, 2017 - Clarus Therapeutics, Inc., today announced the re-submission of its New Drug Application (NDA) for JATENZO™ (formerly Rextoro™), the Company's oral testosterone (T) replacement product for the treatment of low testosterone in hypogonadal men, to…
May 4, 2017 - Apollo Endosurgery, Inc. Reports First Quarter 2017 Results

AUSTIN - May 4, 2017 - Apollo Endosurgery, Inc. ("Apollo") (NASDAQ: APEN), a leader in less invasive medical devices for bariatric and gastrointestinal procedures, today announced financial results for the three months ended March 31, 2017. First Quarter Highlights…
May 1, 2017 - Intact Vascular Adds Howard Rosen to Its Executive Management Team as VP Marketing and Business Development

WAYNE, PA - May 1, 2017 - Intact Vascular, Inc., a developer of medical devices for minimally invasive peripheral vascular procedures, today announced that Howard Rosen has joined its executive management team as Vice President of Marketing and Business Development. In this position,…
April 6, 2017 - Iconic Therapeutics Appoints Julia P. Gregory to Board of Directors

SAN FRANCISCO - April 6, 2017 – Iconic Therapeutics, a clinical stage biopharmaceutical company dedicated to translating knowledge of Tissue Factor biology into new therapeutics for retinal disease and cancer, announced today the addition of Julia P. Gregory to the company’s Board…
March 23, 2017 - Intact Vascular Announces Completion of Enrollment in the Tack Optimized Balloon Angioplasty II (TOBA II) Clinical Trial

WAYNE, PA - March 23, 2017 - Intact Vascular, Inc., a developer of medical devices for minimally invasive peripheral vascular procedures, today announced that its Tack Optimized…
March 15, 2017 - H.I.G. BioHealth Partners Invests in VertiFlex, Inc.

MIAMI – March 15, 2017 - H.I.G. BioHealth Partners (“H.I.G.”), the dedicated healthcare investment affiliate of H.I.G. Capital, a leading global private equity investment firm with $21 billion of equity capital under management,* led a $40M investment in VertiFlex, Inc. (“VertiFlex”…
January 17, 2017 - Apollo Endosurgery Appoints Dr. Christopher J. Gostout as Chief Medical Officer

AUSTIN, TX – January 17, 2017 -Apollo Endosurgery, Inc. (“Apollo” or the “Company”) (Nasdaq: APEN), a leader in less invasive medical devices for bariatric and gastrointestinal procedures, today announced the appointment of Christopher J. Gostout, MD, as its Chief Medical…
January 5, 2017 - Ocera Announces Successful Phase 1 Clinical Study of Orally-Administered OCR-002 in Patients with Cirrhosis

PALO ALTO, CA and RESEARCH TRIANGLE PARK, NC - Jan. 05, 2017 - Ocera Therapeutics, Inc. (NASDAQ:OCRX), today announced positive results from a Phase 1 clinical study of orally-administered OCR-002 (ornithine phenylacetate) in patients with cirrhosis. The Company is developing oral OCR-002…
January 3, 2017 - Intact Vascular Closes on Additional Series B Funding to Advance Development of the Tack Endovascular System® for Peripheral Artery Disease Treatment

WAYNE, PA - January 3, 2017 - Intact Vascular, Inc., a developer of medical devices for minimally invasive peripheral vascular procedures, today announced that current investors New Enterprise Associates, Quaker Partners and H.I.G. BioHealth Partners have exercised their right to invest…
November 14, 2016 - HyperBranch Medical Technology, Inc. Launches Innovative Adherus® AutoSpray Extended Tip (ET) Dural Sealant for Cranial Neurosurgery

DURHAM, NC, November 14, 2016 -- HyperBranch Medical Technology, Inc. announced today that the Company has launched Adherus AutoSpray ET Dural Sealant (Extended Tip) into the United States cranial neurosurgery market. This follows approval from the United States Food and Drug Administration…
August 15, 2016 - TOBA One-Year Clinical Study Results Published in the Journal of Vascular Surgery

WAYNE, PA – August 15, 2016 – Intact Vascular, Inc., a developer of medical devices for minimally invasive peripheral vascular procedures, today announced that the one-year results from its Tack Optimized Balloon Angioplasty…
August 3, 2016 - Ocera Therapeutics Reports Second Quarter 2016 Financial Results and Company Update

PALO ALTO, CA and RESEARCH TRIANGLE PARK, N.C. – August 3, 2016 – Ocera Therapeutics, Inc. (NASDAQ:OCRX), a clinical stage biopharmaceutical company focused on acute and chronic orphan liver diseases, today reported financial results for the quarter ended June 30, 2016, and provided…
June 13, 2016 - Ocera to Present at the JMP Securities Life Sciences Conference

PALO ALTO, CA and RESEARCH TRIANGLE PARK, N.C. - June 13, 2016 - Ocera Therapeutics, Inc. (NASDAQ:OCRX), a clinical stage biopharmaceutical company focused on acute and chronic orphan liver diseases, today announced that Linda Grais, M.D., Chief Executive Officer, will be presenting…
June 2, 2016 - Tack Optimized Balloon Angioplasty III (TOBA III) Clinical Trial Commences Enrollment with First European Implant of the Tack Endovascular System™

WAYNE, PA - June 2, 2016 - Intact Vascular, Inc., a developer of medical devices for minimally invasive peripheral vascular procedures, today announced that its Tack Optimized Balloon Angioplasty III (TOBA III) clinical trial has commenced enrollment, with the first patient treated…
May 20, 2016 - Apollo Endosurgery Features Industry-Leading Endoscopic Procedure Portfolio at Digestive Disease Week® 2016 Conference (DDW)

AUSTIN - May 20, 2016 — Apollo Endosurgery, Inc., a leader in minimally invasive endoscopic surgical products for bariatric and gastrointestinal procedures, will spotlight a multitude of study results for the ORBERA® Gastric Balloon and OverStitch™ Endoscopic Suturing…
May 17, 2016 - Clarus Therapeutics Initiates Phase 3 Clinical Trial of Oral Testosterone Replacement Therapy

NORTHBROOK, Ill. – May 17, 2016 – Clarus Therapeutics, Inc., a men's health specialty pharmaceutical company focused on the development and commercialization of JATENZOTM, its proprietary oral testosterone (T) replacement product (formerly REXTORO), today announced…
April 19, 2016 - H.I.G. BioHealth Partners Completes Successful Sale of NeuWave Medical, Inc. to Ethicon, a Johnson and Johnson Company

MIAMI – April 19, 2016 - H.I.G. BioHealth Partners (“H.I.G.”), the dedicated healthcare investment affiliate of H.I.G. Capital, a leading global private equity investment firm with $19 billion of equity capital under management,* recently announced the sale of NeuWave…
April 5, 2016 - OncoGenex Pharmaceuticals to Present at the 15th Annual Needham Healthcare Conference

BOTHELL, WA. and VANCOUVER, BC - April 5, 2016 -- OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) announced today that John Bencich, Chief Financial Officer at OncoGenex, will present at the 15th Annual Needham Healthcare Conference on April 13, 2016 at the Westin Grand Central Hotel…
April 4, 2016 - CardioFocus' HeartLight® System Granted FDA Approval for Treatment of Atrial Fibrillation (AF)

More than 3,400 patients worldwide treated with HeartLight System to date Validates definitive clinical results from U.S. multi-center pivotal study MARLBOROUGH, MA - April 4, 2016 - CardioFocus, Inc. today announced that it has received premarket approval (PMA) from the U.S. Food and…
March 9, 2016 - OncoGenex Pharmaceuticals, Inc. Reports Financial Results for Year End 2015

BOTHELL, WA. and VANCOUVER, BC - March 9, 2016 -- OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) today announced year end 2015 financial results and provided a summary of anticipated milestones. Financial Results and Anticipated Near-term Milestones As of December 31,…
February 4, 2016 - Alder BioPharmaceuticals to Present at Leerink Partners 5th Annual Global Healthcare Conference

BOTHELL, WA. - Feb. 4, 2016 - Alder BioPharmaceuticals, Inc.,a clinical-stage biopharmaceutical company developing monoclonal antibody therapeutics for the prevention of migraine, Cushing's disease, Congenital Adrenal Hyperplasia and autoimmune and inflammatory diseases, today…
February 4, 2016 - OncoGenex Announces Reduction in Force to Extend Cash Runway and Align Operations with Clinical Development Priorities

BOTHELL, WA. and VANCOUVER, British Columbia - Feb. 4, 2016 - OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) announced today that it is implementing a plan to reduce operating expenses, including a workforce reduction of approximately 27%. The Company expects cost savings associated…
January 4, 2016 - Positive Six-Month Tack Optimized Balloon Angioplasty Below-the-Knee (TOBA-BTK) Results Presented at LINC 2016

WAYNE, PA – Jan. 4, 2016 - Intact Vascular, Inc., a developer of medical devices for minimally invasive peripheral vascular procedures, today announced that positive six-month results from its Tack Optimized Balloon Angioplasty – Below-the-Knee (TOBA-BTK) clinical study were…
December 1, 2015 - OncoGenex Announces Phase 3 AFFINITY Trial with Custirsen Continues Following Interim Analyses

BOTHELL, WA and VANCOUVER, BC - Dec. 1, 2015 -- Following an independent Data Monitoring Committee (DMC) meeting, OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) announced today that its Phase 3 AFFINITY trial is continuing based on the pre-planned interim futility analysis of the intent-to-treat…
November 18, 2015 - NOVADAQ to Participate in the 27th Annual Piper Jaffray Healthcare Conference

TORONTO, ON - November 18, 2015 - Novadaq Technologies Inc. ("NOVADAQ" or the “Company") (NASDAQ:NVDQ; TSX:NDQ), the leading developer and provider of clinically relevant fluorescence imaging solutions for use in surgical and diagnostic procedures, today announced…
November 17, 2015 - ForSight VISION5’s Phase 2 Clinical Data Demonstrating 6-Month IOP-Lowering from a Single Topical Ocular Insert with Very High Retention Rates Presented at American Academy of Ophthalmology;

MENLO PARK, CA, and LAS VEGAS, NV - November 17, 2015 -- ForSight VISION5 announced results of its first randomized, controlled Phase 2 study comparing the investigational HeliosTM bimatoprost ocular insert1 to twice-daily timolol eye drops. The presented data demonstrated that a single…
October 13, 2015 - Alder BioPharmaceuticals Initiates Pivotal Clinical Trial of ALD403 for Preventative Treatment of Frequent Episodic Migraine

BOTHELL, WA, Oct. 13, 2015 – Alder BioPharmaceuticals, Inc. (“Alder”) (NASDAQ: ALDR), a clinical-stage biopharmaceutical company developing monoclonal antibody therapeutics for the treatment of migraine, Cushing’s disease, Congenital Adrenal Hyperplasia and autoimmune…
October 8, 2015 - OncoGenex Announces EMA Support for Phase 3 AFFINITY Trial Protocol Amendment

BOTHELL, WA and VANCOUVER, British Columbia – Oct. 8, 2015 – OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) announced today that the European Medicines Agency (EMA) has completed its review of the proposed amendment to the company's Phase 3 AFFINITY protocol and statistical…
September 3, 2015 - NOVADAQ to Present at the 2015 Morgan Stanley Global Healthcare Conference

TORONTO - September 3, 2015 - Novadaq Technologies Inc. ("NOVADAQ" or the “Company") (NASDAQ:NVDQ; TSX:NDQ), the leading developer and provider of clinically relevant fluorescence imaging solutions for use in surgical and diagnostic procedures,…
September 2, 2015 - Alder BioPharmaceuticals to Present at Wells Fargo 2015 Healthcare Conference

BOTHELL, WA - September 2, 2015 – Alder BioPharmaceuticals, Inc. (“Alder”) (NASDAQ: ALDR), a clinical-stage biopharmaceutical company developing monoclonal antibody therapeutics for the treatment of migraine, Cushing’s disease and autoimmune and inflammatory…
August 13, 2015 - OncoGenex Pharmaceuticals, Inc. Reports Financial Results for Second Quarter 2015

BOTHELL, WA. and VANCOUVER - August 13, 2015 - OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) today announced second quarter 2015 financial results. Recent Developments and Anticipated Near-term Milestones Custirsen - Phase 3 Lung and Prostate Cancer Trials On July…
July 13, 2015 - OncoGenex Announces Custirsen Phase 3 "ENSPIRIT" Trial Continues Following Completion of Final Futility Survival Analysis

BOTHELL, WA and VANCOUVER, BRITISH COLUMBIA - July 13, 2015 - OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) announced today that its Phase 3 ENSPIRIT trial evaluating custirsen in the treatment of advanced or metastatic non-small cell lung cancer (NSCLC) is continuing as planned per…
July 9, 2015 - ForSight VISION5 Appoints Hector Casab Vice President of Finance

MENLO PARK, CA - July 9, 2015 - ForSight VISION5 announced today the appointment of senior finance executive Hector Casab as Vice President of Finance, effective July 13, 2015. Mr. Casab joins ForSight VISION5 from ophthalmic pharmaceutical company Icon Bioscience, Inc., where as Vice…
June 30, 2015 - Alder BioPharmaceuticals Announces Exercise in Full of Option to Purchase Additional Shares

BOTHELL, WA - June 30, 2015 – Alder BioPharmaceuticals, Inc. (NASDAQ: ALDR), a clinical-stage biopharmaceutical company, announced today that the underwriters of its previously announced public offering of common stock have exercised in full their option to purchase an additional…
June 8, 2015 - ForSight VISION5 Selected as a Red Herring Top 100 North America Winner

MENLO PARK, CA - June 8, 2015 - ForSight VISION5 today announced it was selected by Red Herring as one of the Top 100 North America award winners in recognition of its leadership in healthcare innovation. ForSight VISION5 is developing non-invasive drug delivery products to replace…
May 14, 2015 - Intact Vascular Secures $38.9 Million in Series B Financing to Accelerate Development of Endovascular Dissection Repair Technology

WAYNE, PA -- May 14, 2015 Intact Vascular, Inc., a developer of medical devices for minimally invasive peripheral vascular procedures, today announced that it has raised $38.9 million in a Series B venture capital financing. The funds will be used to accelerate the development and FDA…
April 30, 2015 - OncoGenex Announces Custirsen Phase 3 "ENSPIRIT" Trial Update

BOTHELL, WA. and VANCOUVER, BRITISH COLUMBIA - April 30, 2015 -- OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) announced today it has filed an amendment with the U.S. Food and Drug Administration, as well as initiated filing with regulatory agencies in other countries, to amend…
April 30, 2015 - Alder BioPharmaceuticals to Host Conference Call to Discuss First Quarter 2015 Financial and Operating Results

BOTHELL, WA - April 30, 2015 – Alder BioPharmaceuticals, Inc. (“Alder”) (NASDAQ: ALDR), a clinical-stage biopharmaceutical company developing monoclonal antibody therapeutics for the treatment of migraine, Cushing’s disease and autoimmune and inflammatory diseases, today announced…
April 30, 2015 - NOVADAQ To Participate in May Investor Conferences

TORONTO - April 30, 2015 - Novadaq Technologies Inc. (“NOVADAQ” or the “Company”) (NASDAQ:NVDQ; TSX:NDQ), the leading developer and provider of clinically relevant fluorescence imaging solutions for use in surgical and diagnostic procedures, today announced…
April 29, 2015 - Intact Vascular’s First-In-Man Clinical Study Results Published in the Journal of the American College Of Cardiology: Cardiovascular Interventions – Early Experimental and Clinical Experience with a Focal Implant (Tack Endovascular System) for Lower Extremity Post-Angioplasty Dissection Suggests a Safe and Feasible Alternative Treatment

April 29, 2015 - WAYNE, PA - Intact Vascular, Inc., a developer of medical devices for minimally invasive peripheral vascular procedures, today announced the publication of the first clinical experience with supporting preclinical data in the Journal of the American College of Cardiology:…
March 17, 2015 - Apollo Endosurgery Announces Stefanie Cavanaugh as Chief Financial Officer

AUSTIN - March 17, 2015 – Apollo Endosurgery, Inc., a leader in minimally invasive endoscopic surgical products for bariatric and gastrointestinal procedures, today announced that it has appointed Stefanie Cavanaugh as Chief Financial Officer. Cavanaugh brings to Apollo Endosurgery…
February 24, 2015 - OncoGenex and Sarah Cannon Announce Completion of Patient Enrollment in the Spruce™ Clinical Trial Evaluating Apatorsen in Combination with Carboplatin and Pemetrexed in Patients with Advanced Non-Squamous Non-Small Cell Lung Cancer

BOTHELL, WA., & VANCOUVER, BC - February 24, 2015 -- OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) and Sarah Cannon announced today that patient enrollment has been completed in the Spruce™ clinical trial, an investigator-sponsored, randomized, placebo-controlled Phase 2 trial…
February 12, 2015 - OncoGenex Announces Relocation of Corporate Headquarters, Expected to Yield Savings of at Least $4 Million Over Next Three Years

BOTHELL, WA., & VANCOUVER, BC - February 12, 2015 -- OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) today announced that it has executed new lease agreements enabling the relocation of its Bothell, Washington headquarters. Effective March 1, 2015, OncoGenex' new corporate headquarters…
February 10, 2015 - NOVADAQ To Participate in February Investor Conferences

TORONTO - February 10, 2015 - Novadaq Technologies Inc. (“NOVADAQ” or the “Company”) (NASDAQ:NVDQ; TSX:NDQ), the leading developer and provider of clinically relevant fluorescence imaging solutions for use in surgical and diagnostic procedures, announced today that management…
February 10, 2015 - NOVADAQ to Release Fourth Quarter and Full Year 2014 Financial Results on February 25, 2015 – Conference Call to Follow

TORONTO - February 10, 2015 - Novadaq® Technologies Inc. ("NOVADAQ" or the “Company") (NASDAQ:NVDQ;TSX:NDQ), the leading developer and provider of clinically relevant fluorescence imaging solutions for use in surgical and diagnostic procedures, will announce its fourth quarter and…
January 27, 2015 - Positive Twelve-Month Tack Optimized Balloon Angioplasty (TOBA) Results Presented at LINC 2015

WAYNE, PA -- January 27, 2015 -(BUSINESS WIRE)-- Intact Vascular, Inc., a developer of medical devices for minimally invasive peripheral vascular procedures, today announced that positive twelve-month results from its Tack Optimized Balloon Angioplasty (TOBA) clinical…
January 16, 2015 - OncoGenex Announces Update on Phase 3 AFFINITY Trial Evaluating Custirsen in Men with Metastatic Castrate-Resistant Prostate Cancer

BOTHELL, WA., & VANCOUVER, BC - January 16, 2015 -- OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) today announced that the AFFINITY trial is continuing as planned based upon completion of the interim futility analysis and the recommendation of the Independent Data Monitoring Committee…
November 6, 2014 - NOVADAQ Reports Third Quarter 2014 Financial Results

TORONTO - November 6, 2014 - Novadaq® Technologies Inc. (“NOVADAQ” or the “Company”) (NASDAQ:NVDQ; TSX:NDQ), the leading developer and provider of clinically relevant fluorescence imaging solutions for use in surgical and diagnostic procedures, today announced financial results…
November 4, 2014 - Intact Vascular Announces Completion of TOBA-BTK Trial Enrollment

WAYNE, PA - November 4, 2014 - Intact Vascular, a medical device company and developer of products for minimally invasive peripheral vascular procedures, today announced its completion of the TOBA-BTK Study, Tack Optimized Balloon Angioplasty - Below the Knee Study. This multi-center…
November 3, 2014 - Alder BioPharmaceuticals Reports Third Quarter 2014 Financial and Operating Results

BOTHELL, WA - November 3, 2014 – Alder BioPharmaceuticals, Inc. (“Alder”) (NASDAQ: ALDR), a clinical-stage biopharmaceutical company developing monoclonal antibody therapeutics for the treatment of migraine, autoimmune and inflammatory diseases, today provided recent corporate…
October 30, 2014 - OncoGenex Pharmaceuticals, Inc. Reports Financial Results for Third Quarter 2014

BOTHELL, WA., & VANCOUVER, BC - October 30, 2014 - OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) today provided a summary of clinical developments and announced third quarter 2014 financial results. Q3 2014 Highlights The custirsen Phase 3 AFFINITY trial successfully…
October 16, 2014 - ForSight VISION5 Names Lisa Garrett as Vice President of Finance and Administration; Clinical Data for Helios™ Insert to be Presented at American Academy of Ophthalmology

MENLO PARK, CA. - October 16, 2014 - ForSight VISION5 is pleased to announce that Lisa Garrett has joined the company as Vice President of Finance and Administration from Medtronic. Earlier this year, Medtronic acquired Corventis, Inc., for which Ms. Garrett served as Chief Financial…
September 23, 2014 - H.I.G. Capital Expands Investor Relations Team with the Addition of Jordan Peer as Managing Director and Head of IR and Thierry Edde as a Director

NEW YORK & LONDON – September 23, 2014 – H.I.G. Capital ("H.I.G."), a leading global private investment firm with more than $17 billion of capital under management,* announced the expansion of its investor relations team with two new hires. Jordan Peer joins the firm as Managing…
September 18, 2014 - Clarus Therapeutics Reports FDA Advisory Committees Vote on REXTORO(TM) for Low Testosterone in Men

NORTHBROOK, Ill. - Sept. 18, 2014 - Clarus Therapeutics, Inc. announced today that the U.S. Food and Drug Administration's (FDA) Bone, Reproductive and Urologic Drugs Advisory Committee and Drug Safety and Risk Management Advisory Committee voted 18-3 that the overall benefit/risk profile…
August 7, 2014 - OncoGenex Pharmaceuticals, Inc. Reports Financial Results for Second Quarter 2014

BOTHELL, WA. & VANCOUVER, BC - August 7, 2014 - OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) today provided a summary of clinical developments and announced second quarter 2014 financial results. Clinical Developments and Anticipated Milestones Apatorsen The OncoGenex…
August 5, 2014 - Alder BioPharmaceuticals Reports Second Quarter 2014 Financial and Operating Results

BOTHELL, WA. - August 5, 2014 – Alder BioPharmaceuticals, Inc. (“Alder”) (NASDAQ: ALDR), a clinical-stage biopharmaceutical company developing monoclonal antibody therapeutics for the treatment of migraine, autoimmune and inflammatory diseases, today provided recent corporate…
August 5, 2014 - NOVADAQ Reports Second Quarter 2014 Financial Results

TORONTO - August 5, 2014 - Novadaq® Technologies Inc. (“NOVADAQ” or the “Company”) (NASDAQ: NVDQ, TSX: NDQ), the leading developer and provider of clinically relevant imaging solutions for use in surgical and diagnostic procedures, today announced financial results for its…
July 29, 2014 - Apollo Endosurgery Announces Affordable Financing Service to Increase Patient Access to the LAP-BAND® System

AUSTIN - July 29, 2014 — Apollo Endosurgery, Inc., a leader in minimally invasive endoscopic surgical products for bariatric and gastrointestinal procedures, today announced the company has partnered with American Healthcare Lending to offer affordable financing for the LAP-BAND®…
July 21, 2014 - Clarus Therapeutics Expands Board of Directors with Appointment of Two Pharmaceutical Industry Veterans

NORTHBROOK, Ill. – July 21, 2014 – Clarus Therapeutics, Inc., a men’s health specialty pharmaceutical company focused on the development and commercialization of REXTORO®, an oral testosterone (T) replacement product, today announced the expansion of its Board of Directors from…
July 14, 2014 - Intact Vascular, Inc. Hires Bruce Shook as President and Chief Executive Officer

WAYNE, PA. - JULY 14, 2014 - Intact Vascular, Inc., a developer of medical devices for minimally invasive peripheral vascular procedures, today announced that Bruce J. Shook is joining the Company as President and Chief Executive Officer and as a member of its Board of Directors. Mr.…
July 1, 2014 - OncoGenex Announces Cedar™ Clinical Trial Evaluating Apatorsen in Combination with Chemotherapy in Advanced Squamous Cell Lung Cancer is Now Open for Enrollment

BOTHELL, WA & VANCOUVER, BC - July 1, 2014 - OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) today announced initiation of the Cedar™ clinical trial, an investigator-sponsored, randomized, open-label Phase 2 trial evaluating apatorsen in previously untreated patients with advanced…
June 27, 2014 - Alder BioPharmaceuticals Added to Russell 3000® Index

BOTHELL, WA - June 27, 2014 — Alder BioPharmaceuticals, Inc., (“Alder”) (NASDAQ: ALDR), a clinical-stage biopharmaceutical company developing monoclonal antibody therapeutics for the treatment of migraine, autoimmune and inflammatory diseases, today announced that Alder will be…
June 22, 2014 - Clarus Therapeutics Presents Phase 3 Data for Rextoro® for Men with Hypogonadism

NORTHBROOK, IL – June 22, 2014 – Clarus Therapeutics, Inc., a men’s health specialty pharmaceutical company focused on the development and commercialization of REXTORO ( (Testosterone Undecanoate), an oral testosterone (T) replacement product, today presented Phase 3 clinical…
June 16, 2014 - Apollo Endosurgery Revitalizes the LAP-BAND® System with New “It Fits” Campaign

AUSTIN - June 16, 2014 – Apollo Endosurgery, Inc., the leader in minimally invasive endoscopic surgical products for bariatric and gastrointestinal procedures, today announced the launch of the “It Fits” campaign, aimed at rejuvenating the LAP-BAND® System and educating a broad…
June 12, 2014 - Clarus Therapeutics Secures $31.5 Million in Financing

NORTHBROOK, IL. – June 12, 2014 - Clarus Therapeutics, Inc., a men’s health specialty pharmaceutical company focused on the development and commercialization of REXTORO, an oral testosterone (T) replacement product, today announced that it has issued $31.5 million of 8% convertible…
May 28, 2014 - Clarus Therapeutics to Present Phase 3 Data for Rextoro(R) at ICE/ENDO 2014

NORTHBROOK, IL - May 28, 2014 - Clarus Therapeutics, Inc., a men's health specialty pharmaceutical company focused on the development and commercialization of REXTORO, an oral testosterone (T) replacement product, today announced the presentation of two posters at the 16th International…
May 12, 2014 - NOVADAQ Completes Acquisition of Aïmago SA

TORONTO - May 12, 2014 - With reference to the news release dated April 24, 2014, Novadaq® Technologies Inc. ("NOVADAQ" or the "Company") (NASDAQ:NVDQ) (TSX:NDQ), the leading developer and provider of clinically relevant imaging solutions for use in surgical and diagnostic procedures,…
May 8, 2014 - Alder BioPharmaceuticals Announces Pricing of Initial Public Offering

BOTHELL, WA - May 8, 2014 – Alder BioPharmaceuticals, Inc. (NASDAQ: ALDR), a clinicalstage biopharmaceutical company, announced today the pricing of its initial public offering of 8,000,000 shares of its common stock at a price to the public of $10.00 per share. The shares are expected…
April 16, 2014 - ForSight VISION5 Completes $15MM Series C Funding Round Company Finishes Enrolling Phase 2 Clinical Study

MENLO PARK, CA - April 16, 2014 - ForSight VISION5 is pleased to announce it has recently closed its Series C round of funding and has also completed enrollment in its Phase 2 Clinical Study for the HeliosTM ocular insert, its lead product candidate. ForSight VISION5 is developing non‐invasive…
March 19, 2014 - H.I.G. Capital Launches H.I.G. Healthcare Royalty & Credit

MIAMI – March 19, 2014 - H.I.G. Capital, a leading global investment firm with over $15 billion of capital under management, announced today the launch of H.I.G. Healthcare Royalty & Credit. H.I.G. Healthcare Royalty & Credit will focus on making income generating investments…
February 3, 2014 - H.I.G. Capital Opens Milan Office

MILAN & MIAMI – February 3, 2014 - H.I.G. Capital, a leading global private equity firm with more than $13 billion of equity capital under management, announced today that it has opened a Milan office and appointed Raffaele Legnani as a Managing Director to lead its efforts in…
January 8, 2014 - Cardeas Pharma Announces that FDA Grants QIDP Designation and Fast Track Review for the Company’s Antibiotic Combination Product

SEATTLE, WA - January 8, 2014 - Cardeas Pharma Corporation, a biopharmaceutical company focused on the development of innovative therapies for the treatment of multi-drug resistant (MDR) bacterial infections, announced today that the U.S. Food and Drug Administration (FDA) has designated…
December 10, 2013 - Novadaq to Present at January Investor Conferences

TORONTO, ONTARIO - December 10, 2013 - Novadaq® Technologies Inc. (“Novadaq” or the “Company”) (NASDAQ: NVDQ, TSX: NDQ), a developer of clinically-relevant imaging solutions for use in surgical and outpatient wound care procedures, today announced that…
December 2, 2013 - Apollo Endosurgery Completes Acquisition of Allergan Inc.’s Obesity Intervention Division

AUSTIN, TX - December 2, 2013 – Apollo Endosurgery, Inc., a leading developer of medical devices for endoscopic surgical procedures, today announced the completion of the acquisition of the obesity intervention division of Allergan, Inc., which manufactures and sells weight loss solutions…
November 7, 2013 - OncoGenex Pharmaceuticals, Inc. Reports Financial Results for Third Quarter 2013 and Addresses Key Questions from Investors on Quarterly Conference Call

BOTHELL, WA & VANCOUVER, BC - November. 7, 2013 –OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) today announced third quarter 2013 financial results and will address frequently asked questions from investors during the quarterly conference call. Questions, including recent…
October 31, 2013 - H.I.G. Capital Awarded South America Private Equity Firm of the Year and South America M&A Deal of the Year

RIO DE JANEIRO & MIAMI – October 31, 2013 - H.I.G. Capital, LLC ("H.I.G."), a leading global private equity investment firm with more than $13 billion of equity capital under management, announced today that the Global M&A Network awarded the firm with the South America Private…
October 1, 2013 - Intact Vascular Announces Completion of Enrollment of the Tack Optimized Balloon Angioplasty (TOBA) Study

WAYNE, PA - October 1, 2013 - Intact Vascular, Inc., a developer of medical devices for minimally invasive peripheral vascular procedures, today announced the completion of enrollment of the Tack Optimized Balloon Angioplasty (TOBA) study. The purpose of this multi-center study is to…
August 8, 2013 - OncoGenex Pharmaceuticals, Inc. Provides Clinical Development Program Overview and Reports Financial Results for Second Quarter 2013

BOTHELL, WA. and VANCOUVER, BC - August 8, 2013 - OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) today provided an overview of clinical development activities for its two product candidates, custirsen and apatorsen (OGX-427), and announced second quarter 2013 financial results. Custirsen…
August 1, 2013 - Novadaq Reports Second Quarter 2013 Financial Results

TORONTO, ONTARIO - August 1, 2013 - Novadaq® Technologies Inc. (“Novadaq” or the “Company”) (NASDAQ: NVDQ, TSX: NDQ), a developer of clinically-relevant fluorescence imaging solutions for use in surgical and outpatient wound care procedures, today announced financial results…
July 1, 2013 - Clarus Therapeutics Bolsters Executive Team with Addition of Chief Medical and Chief Scientific Officers

NORTHBROOK, Ill – July 1, 2013 – Clarus Therapeutics, Inc., today announced the hiring of Theodore M. Danoff, M.D., Ph.D. and Wael A. Salameh, M.D., FACP to fill the newly created posts of VP clinical development & chief medical officer and VP medical affairs & chief scientific…
May 22, 2013 - Cardeas Pharma Completes $34 Million in Series B Financing

SEATTLE - May 22, 2013 - Cardeas Pharma Corporation, a biopharmaceutical company focused on the development of innovative therapies for the treatment of multi-drug resistant (MDR) bacterial infections, announced today the completion of a $34 million Series B round of financing. The…
May 1, 2013 - Novadaq Announces the Sale of US$50.3 Million of Common Shares

TORONTO, ONTARIO - May 1, 2013 - Novadaq® Technologies Inc. (“Novadaq” or the “Company”) (NASDAQ: NVDQ, TSX: NDQ), a developer of clinically-relevant fluorescence imaging solutions for use in surgical and outpatient wound care procedures, announced today the sale of US$50.3…
May 1, 2013 - OncoGenex Announces Plans for the Initiation of the Rainier™ Clinical Trial Evaluating OGX-427 in Combination with ABRAXANE® plus Gemcitabine in Patients with Metastatic Pancreatic Cancer

BOTHELL, WASH. and VANCOUVER, BRITISH COLUMBIA - May 1, 2013 - OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) today announced plans for the initiation of the Rainier™ trial, an investigator-sponsored, randomized, placebo-controlled Phase 2 trial evaluating OGX-427 in combination with…
April 23, 2013 - Tranzyme Pharma and Ocera Therapeutics Announce Merger Agreement

RESEARCH TRIANGLE PARK, N.C. and SAN DIEGO - April 23, 2013 - Tranzyme Pharma (Nasdaq:TZYM) ("Tranzyme"), a biopharmaceutical company focused on discovering, developing and commercializing novel, mechanism-based therapeutics, and Ocera Therapeutics, Inc. ("Ocera"), a privately held…
April 2, 2013 - Apollo Endosurgery’s OverStitch™ Endoscopic Suturing Platform Launches in Europe

AUSTIN, TX - April 2, 2013 – Apollo Endosurgery, Inc., a company focused on the development of devices that enable a new generation of endoscopic surgical procedures, announced that its OverStitch™ Endoscopic Suturing System has received the European Union’s CE Mark. The company…
March 7, 2013 - OncoGenex Pharmaceuticals, Inc. Provides Update on Clinical Development Program and Reports Financial Results for Fourth Quarter and Year End 2012

BOTHELL, WASHINGTON and VANCOUVER, BRITISH COLUMBIA - March 7, 2013 - OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) today highlighted key clinical development activities for its two product candidates, custirsen and OGX-427, and announced its fourth quarter and year end 2012 financial…
February 8, 2013 - Tranzyme Pharma Announces Exploration of Strategic Alternatives

RESEARCH TRIANGLE PARK, N.C. - February 8, 2013 - Tranzyme, Inc. (Nasdaq:TZYM) announced today that its Board of Directors has made a determination to explore and evaluate strategic alternatives, including the possibility of a merger, sale, other form of business combination, or other…
February 7, 2013 - Novadaq Reports 2012 Fourth Quarter and Full Year Financial Results

TORONTO, ONTARIO — February 7, 2013 – Novadaq® Technologies Inc. (“Novadaq” or the “Company”) (NASDAQ: NVDQ, TSX: NDQ,), a developer of clinically-relevant fluorescence imaging solutions for use in surgical procedures, today announced financial…
January 4, 2013 - Tranzyme Pharma Announces Successful Completion of Drug Discovery Collaboration With Bristol-Myers Squibb

Research Triangle Park, N.C. - January 4, 2013 – Tranzyme Pharma (Nasdaq:TZYM), a biopharmaceutical company focused on discovering, developing and commercializing novel small molecule macrocyclic compounds, today announced the successful completion of its chemistry-based drug discovery…
December 19, 2012 - OncoGenex Announces Initiation of Randomized Phase 2 "PACIFIC" Study of OGX-427 in combination with Zytiga® in Men with Metastatic Castrate-Resistant Prostate Cancer

Bothell, WA and Vancouver, BC – December 19, 2012 – OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) announced today the initiation of PACIFIC, an investigator-sponsored, randomized Phase 2 study evaluating OGX-427 in men with metastatic castrate-resistant prostate cancer (CRPC) who…
December 5, 2012 - Novadaq Announces First PINPOINT Purchase Order

Toronto, Ontario - December 5, 2012 – Novadaq® Technologies Inc. (“Novadaq” or the “Company”) (NASDAQ: NVDQ, TSX: NDQ), a developer of real-time medical imaging systems for use in the operating room, today announced that Maimonides Medical Center in Brooklyn, New York, is…
September 5, 2012 - Intact Vascular Announces $15.5 MM Series A Financing and Names Dennis Wahr, M.D. as Chairman

WAYNE, PA - September 5, 2012 -Intact Vascular, a medical device company and developer of products for minimally invasive peripheral vascular procedures, today announced the completion of a $15.5 MM Series A financing. The proceeds from this financing will be used to continue clinical…
September 5, 2012 - NeuWave Medical, Inc. Announces $14 Million Financing Led by H.I.G. BioVentures to Further Commercial Success of Microwave-Based Ablation Tools

MADISON, WI – September 5, 2012 – Medical device company, NeuWave Medical, announced today that it has raised a $14 million Series B financing, led by new investor H.I.G. BioVentures, with participation from existing shareholders, including Venture Investors, WARF and the State…
August 9, 2012 - Tranzyme Pharma Announces Second Quarter 2012 Financial Results

RESEARCH TRIANGLE PARK, N.C. - August 9, 2012 - Tranzyme Pharma (Nasdaq:TZYM), a biopharmaceutical company focused on discovering, developing and commercializing novel, first-in-class small molecule therapeutics for the treatment of gastrointestinal (GI) motility disorders, today announced…
June 6, 2012 - Tranzyme Pharma to Present TZP-102 Data at ADA June 8-12, 2012 in Philadelphia, PA

RESEARCH TRIANGLE PARK, N.C. - June 6, 2012 - Tranzyme Pharma (Nasdaq:TZYM), today announced that Niels Ejskjaer, M.D., Ph.D., Department of Medicine MEA (Endocrinology and Diabetes) Aarhus University Hospital, Aarhus Denmark will present a poster entitled TZP-102 Ghrelin Receptor Agonist…
June 4, 2012 - Data from a Phase 2 Study Presented at the 2012 ASCO Annual Meeting Continues to Show Early Activity of OGX-427 in Patients with Prostate Cancer

BOTHELL, WASHINGTON and VANCOUVER, BRITISH COLUMBIA - June 4, 2012 - OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) announced today data from a Phase 2 study of its investigational compound OGX-427 in chemotherapy-naive metastatic castration resistant prostate cancer (mCRPC) patients…
May 21, 2012 - Apollo Endosurgery Names Former Covidien Chairman and CEO Richard J. Meelia to Board of Directors

AUSTIN, TX - May 21, 2012 - Apollo Endosurgery, Inc., a company focused on the development of devices that advance therapeutic endoscopy to enable an entirely new generation of endoscopic surgical procedures, today announced that Richard J. Meelia, former CEO and Chairman of Covidien…
May 16, 2012 - HyperBranch Receives CE Mark for Adherus™ AutoSpray Dural Sealant

DURHAM, NC - May 16, 2012 - HyperBranch Medical Technology, Inc. announced today that it has received CE Marking for Adherus™ AutoSpray Dural Sealant. Adherus™ AutoSpray is a novel delivery system used for the delivery HyperBranch’s dural sealant which is used in cranial and spine…
May 11, 2012 - Apollo Endosurgery Introduces New "Flexible Surgery" Products at SAGES 2010

AUSTIN, TX - May, 2010 - Apollo Endosurgery, Inc. has just concluded a successful participation at the 12th World Congress of Endoscopic Surgery (hosted by SAGES and CAGS). This was the company’s first booth exhibit and they previewed two new products: The OverStitch™ Endoscopic…
May 7, 2012 - Alder BioPharmaceuticals Inc. Initiates Phase 1 Clinical Study of Antibody Therapeutic Candidate for Treatment of Migraine, ALD403

BOTHELL, WASHINGTON - May 7, 2012 - Alder BioPharmaceuticals Inc. today announced the initiation of a Phase 1 clinical study of its antibody therapeutic candidate, ALD403, targeting thecalcitonin gene-related peptide (CGRP) for treatment of migraine. The placebo-controlled, single ascending-dose…
May 1, 2012 - Clarus Therapeutics Completes Patient Enrollment in Phase 3 Study of Its Proprietary Oral Testosterone Replacement Therapy

NORTHBROOK, Ill - May 1, 2012 - Clarus Therapeutics, Inc., today announced that patient enrollment has been completed in the Company’s pivotal Phase 3 clinical trial of its proprietary oral testosterone (T) replacement product (CLR-610). Primary endpoint of the ongoing study is the…
April 19, 2012 - Alder BioPharmaceuticals Inc. Closes $38 Million Series D Financing to Accelerate Clinical Development of its Pipeline of Antibody Therapeutics

BOTHELL, WASHINGTON - April 19, 2012 - Alder BioPharmaceuticals Inc. today announced the closing of a $38 million Series D financing to support the development of the company’s clinical stage pipeline. The financing was led by a new investor, Novo Ventures, and joined by existing…
April 10, 2012 - H.I.G. BioVentures Closes $268 Million Life Sciences Fund

MIAMI - April 10, 2012 - H.I.G. Capital, LLC announced today the successful closing of H.I.G. BioVentures II, L.P. (the “Fund”). The Fund held its final closing on March 28, 2012, and was over-subscribed with total aggregate commitments of $268 million, exceeding…
April 10, 2012 - H.I.G. BioVentures Closes $268 Million Life Sciences Fund

MIAMI - April 10, 2012 - H.I.G. Capital, LLC announced today the successful closing of H.I.G. BioVentures II, L.P. (the “Fund”). The Fund held its final closing on March 28, 2012, and was over-subscribed with total aggregate commitments of $268 million, exceeding its $250 million…
February 7, 2012 - H.I.G. Capital Opens Madrid Office

MADRID & MIAMI - February 7, 2012 - H.I.G. Capital, a leading global private equity firm with more than $8.5 billion of equity capital under management, announced today that it has opened a Madrid office and appointed Jaime Bergel as a Managing…
February 6, 2012 - Apollo Endosurgery Announces $47.6M Financing

AUSTIN, TX - February 6, 2012 - Apollo Endosurgery, Inc., a company focused on the development of devices that advance therapeutic endoscopy to enable an entirely new generation of minimally invasive, scarless surgical procedures, today announced a $47.6 million financing. New investors…
February 1, 2012 - H.I.G. Capital Expands into Latin America with Rio de Janeiro Office

RIO DE JANEIRO & MIAMI - February 1, 2012 - H.I.G. Capital, a leading global private equity firm with more than $8.5 billion of equity capital under management, announced today that it has opened an office in Rio de Janeiro, and appointed Fernando Marques Oliveira…
January 4, 2012 - FDA Clears Apollo Endosurgery's SuMO™ Endoscopic Tissue Access and Resection System

AUSTIN, TX -January 4, 2012 - Apollo Endosurgery Inc. announced today that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for its SuMO™ endoscopic tissue access and resection system. Apollo Endosurgery designed the scarless surgery system to help surgeons…
January 3, 2012 - Novadaq Names MAQUET Cardiovascular Exclusive U.S. Distributor of CO2 Heart Laser Products

TORONTO -January 3, 2012- Novadaq® Technologies Inc., a developer of real-time imaging systems for use in the operating room, and MAQUET Cardiovascular, a leader in providing innovative products for cardiac surgery, vascular intervention and cardiac support, announced today that the…
December 22, 2011 - Novadaq to Present at the 14th Annual Needham Growth Conference

TORONTO -December 22, 2011-Novadaq® Technologies Inc. (TSX: NDQ), a developer of real-time imaging systems for use in the operating room, announced today that Dr. David Martin, the company’s vice president, business development and investor relations, will present Novadaq’s corporate…
December 7, 2011 - Tranzyme Pharma and Norgine Complete Enrollment in First of Two Pivotal Phase 3 Trials of Ulimorelin

RESEARCH TRIANGLE PARK, NC - December 7, 2011 - Tranzyme Pharma and Norgine B.V. today announced completion of patient enrollment in ULISES 007, the first of two Phase 3 pivotal trials of ulimorelin for the acceleration of gastrointestinal (GI) recovery in patients undergoing partial…
November 30, 2011 - Novadaq and KCI Sign Commercialization Agreements for the SPY System

TORONTO-November 30, 2011-Novadaq® Technologies Inc., a developer of real-time imaging systems for use in the operating room, announced today that the company has signed exclusive multi-year sales and marketing agreements with Kinetic Concepts, Inc. (KCI), and its LifeCell business…
November 29, 2011 - Quinnova Pharmaceuticals, Inc. Launches New Website Targeted to Patients and Healthcare Providers

NEWTOWN, PA - November 29, 2011 - Quinnova Pharmaceuticals, Inc. announces the launch of its new website, designed for an enhanced patient and physician experience. The totally revamped site contains valuable patient information about various dermatologic conditions, as well as an overview…
November 8, 2011 - Tranzyme Pharma Announces the Extension of its Chemistry-Based Drug Discovery Collaboration with Bristol-Myers Squibb

RESEARCH TRIANGLE PARK, NC - November 8, 2011 - Tranzyme Pharma today announced the extension of its chemistry-based drug discovery collaboration with Bristol-Myers Squibb Company to discover, develop and commercialize novel macrocyclic compounds directed against targets of interest…
November 7, 2011 - Quinnova Pharmaceuticals, Inc. Announces the Launch of Neosalus® Lotion

NEWTOWN, PA - November 7, 2011 - Quinnova Pharmaceuticals, Inc. announces the launch of Neosalus® Lotion, the newest addition to its Neosalus® line. Neosalus® Lotion is a non---steroidal anti-inflammatory prescription product that offers topical treatment for the management of skin…
October 26, 2011 - OncoGenex Announces Publication of OGX-427 Pre-Clinical Data in Pancreatic Cancer

BOTHELL, WASHINGTON & VANCOUVER, BRITISH COLUMBIA - October 26, 2011 - OncoGenex Pharmaceuticals, Inc. announced today that pre-clinical data evaluating its investigational compound, OGX-427, in pancreatic cancer was published online in Cell Death and Disease. OGX-427 is designed…
October 24, 2011 - Novadaq to Release Q3-2011 Financial Results on November 4 – Conference Call to Follow

TORONTO-October 24, 2011-Novadaq® Technologies Inc. a developer of real-time imaging systems for use in the operating room, will announce its third quarter 2011 financial results before markets open on Friday, November 4, 2011. Novadaq is pleased to invite all interested parties to…
October 20, 2011 - Tranzyme Pharma Ranked Number 54 Fastest Growing Company in North America on Deloitte's 2011 Technology Fast 500(TM)

RESEARCH TRIANGLE PARK, NC - October 20, 2011 -Tranzyme Pharma today announced it ranked No. 54 on Deloitte's Technology Fast 500™, ranking of the 500 fastest growing technology, media, telecommunications, life sciences and clean technology companies in North America. Tranzyme Pharma…
October 20, 2011 - OncoGenex Pharmaceuticals Initiates an International, Randomized, Phase II Clinical Trial Evaluating OGX-427 in Advanced Bladder Cancer

BOTHELL, WASHINGTON & VANCOUVER, BRITISH COLUMBIA - October 20, 2011 - OncoGenex Pharmaceuticals, Inc. announced today that it has initiated patient enrollment in a randomized, Phase II clinical trial evaluating OGX-427, an inhibitor of heat shock protein 27 (Hsp27), in patients…
October 18, 2011 - Tranzyme Pharma Names Former Gilead Executive Franck Rousseau, M.D. Chief Medical Officer

RESEARCH TRIANGLE PARK, NC - October 18, 2011 - Tranzyme Pharma today announced the appointment of Franck Rousseau, M.D. to the newly created position of Chief Medical Officer. Dr. Rousseau will oversee the development of Tranzyme's clinical and preclinical portfolio including its most…
October 6, 2011 - Novadaq Reports 165 System Shipments During Third Quarter 2011

TORONTO-October 6, 2011-Novadaq® Technologies Inc. (TSX: NDQ), a developer of real-time imaging systems for use in the operating room, announced today that it shipped a total of 165 fluorescence imaging systems during the quarter ended September 30, 2011. This compares to 92 systems…
October 5, 2011 - Tranzyme Pharma Initiates Dosing in Phase 2b Trial of TZP-102 in Diabetic Patients With Gastroparesis

RESEARCH TRIANGLE PARK, N.C. - October 5, 2011 - Tranzyme Pharma announced that it has dosed its first patient in a Phase 2b, 12-week trial of its first-in-class, oral, gastrointestinal (GI) motility drug candidate, TZP-102. The trial will be conducted in patients suffering from diabetic…
September 29, 2011 - Apollo Endosurgery® Signs Agreement with Apollo Hospitals Group to Advance Incisionless Bariatric Surgery in India

AUSTIN, TX - September 29, 2011 - Apollo Endosurgery®, Inc. announced today that it has signed a Memorandum of Understanding (MOU) with Apollo Hospitals Group, one of the largest healthcare networks in Asia, to promote the adoption of incisionless bariatric procedures with flexible…
September 21, 2011 - A Phase III Clinical Trial Testing Long-Term Pain Management in Men With Metastatic Castrate-Resistant Prostate Cancer Is Open and Enrolling

BOTHELL, WA & VANCOUVER, BC - September 21, 2011 - Strides have been made in the last few years in improving treatment and extending survival for men with metastatic castrate-resistant prostate cancer (mCRPC), meaning prostate cancer that no longer responds to hormone therapy and…
September 20, 2011 - Tranzyme Pharma Appoints George Abercrombie to Its Board of Directors

RESEARCH TRIANGLE PARK, N.C. - September 20, 2011 - Tranzyme Pharma announced the appointment of George B. Abercrombie, R.Ph., M.B.A. to its Board of Directors and to serve on its Nominating and Corporate Governance Committee. Mr. Abercrombie brings more than 30 years of pharmaceutical…
September 19, 2011 - OncoGenex Announces Completion of a Special Protocol Assessment (SPA) Amendment with the FDA Increasing Patient Eligibility for the Custirsen Phase III Prostate Cancer SATURN Clinical Trial

BOTHELL, WA & VANCOUVER - September 19, 2011 - OncoGenex announced that the company has successfully completed an amendment to the approved SPA with the U.S. Food and Drug Administration (FDA) to expand the inclusion criteria for the Prostate Cancer SATURN Clinical Trial - a Phase…
September 12, 2011 - Tranzyme Pharma Announces Presentation of Additional Data for Its Oral Drug Candidate, TZP-102, at Annual Neurodiab Meeting in Porto, Portugal

RESEARCH TRIANGLE PARK, N.C. - September 12, 2011 - Tranzyme Pharma announced that Niels Ejskjaer, M.D., Ph.D., Department of Endocrinology M, Aarhus University Hospital, Denmark, presented additional data from Tranzyme's Phase 2, 28-day study of its oral ghrelin agonist, TZP-102, supporting…
September 6, 2011 - OncoGenex Announces Publication of Custirsen Phase II Clinical and Pre-Clinical Data in Leading Cancer Journals

BOTHELL, WA & VANCOUVER - September 6, 2011 - OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) announced today that data from two studies, a Phase II clinical study and a pre-clinical study, evaluating the investigational compound custirsen (OGX-011/TV-1011), were published in the…
August 29, 2011 - Apollo Endosurgery® Announces First Incisionless Full-thickness Resection of a Colonic Polyp

BARCELONA, SPAIN - August 29, 2011 -Gastroenterologists José-Ramón Armengol Miró, MD, and Sergey V. Kanstevoy, MD, at Vall d’Hebron University Hospital in Barcelona, Spain are the first in the world to successfully perform a full-thickness resection of a colonic polyp without the…
August 9, 2011 - David Moore Joins Tranzyme Pharma as Vice President, Commercial Operations

RESEARCH TRIANGLE PARK, NC - August 9, 2011 - Tranzyme Pharma, announced that David Moore has joined the Company as Vice President, Commercial Operations, a newly created management position. In this role, Mr. Moore will be responsible for market development-related activities for Tranzyme's…
July 25, 2011 - Novadaq to Release Q2-2011 Financial Results on August 4 – Conference Call to Follow

TORONTO, ONTARIO - July 25, 2011 - Novadaq® Technologies Inc. (TSX: NDQ), a developer of real-time imaging systems for use in the operating room, will announce its second quarter 2011 financial results after market close on Thursday, August 4, 2011. Novadaq is pleased to invite all…
July 20, 2011 - Tranzyme Pharma's Richard Eisenstadt Wins Triangle Business Journal CFO of the Year Award

RESEARCH TRIANGLE PARK, N.C. - July 20, 2011 - Tranzyme Pharma (Nasdaq:TZYM) today announced that its Chief Financial Officer, Richard Eisenstadt, has been honored as a Triangle Business Journal CFO of the Year for 2011. "We're all very proud of Rich and congratulate him on being recognized…
June 7, 2011 - Apollo Endosurgery Taps Michael Doty for CFO

AUSTIN, TX - June 7, 2011 - Apollo Endosurgery, Inc., a leading company in the emerging field of flexible surgery, announced today the appointment of Michael J. Doty as Chief Financial Officer (CFO). Doty most recently served as CFO for Tornier BV, and prepared the company for one of…
June 6, 2011 - Data from Pre-Clinical Studies Presented at the 2011 ASCO Annual Meeting Show Potential Combinability of Custirsen with MDV3100 and Hsp90 Inhibitors to Enhance Anti-Tumor Activity in Prostate Cancer

BOTHELL, WA and VANCOUVER, BC - June 6, 2011 - OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) announced new data showing how the company's lead investigational compound, custirsen (OGX-011/TV-1011), may work with innovative therapies MDV3100 and heat-shock protein 90 (Hsp90) inhibitors…
May 24, 2011 - Novadaq Announces Appointment of G. Steven Burrill to Its Board of Directors

TORONTO, ONTARIO - May 24, 2011 - Novadaq® Technologies Inc. (TSX: NDQ), a developer of real-time imaging systems for use in the operating room, today announced that G. Steven Burrill has been appointed to the Company’s Board of Directors. Mr. Burrill has been involved in the growth…
May 19, 2011 - Teva and OncoGenex to Present Data on Custirsen in Prostate Cancer at the 2011 ASCO Annual Meeting

JERUSALEM & BOTHELL, WA and VANCOUVER, BC - May 19, 2011 - Teva Pharmaceutical Industries Ltd. (NASDAQ:TEVA) and OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) announced today that data from three studies of their investigational compound custirsen (OGX-011/TV-1011) in castrate…
May 18, 2011 - Novadaq to Present at BioFinance 2011

TORONTO, ONTARIO -May 18, 2011-Novadaq® Technologies Inc. (TSX: NDQ), a developer of real-time medical imaging systems for use in the operating room, today announced that Dr. Arun Menawat, the Company’s President and Chief Executive Officer, will present at BioFinance 2011 on Wednesday,…
May 18, 2011 - Novadaq Appoints David C. Martin Vice President, Business Development and Investor Relations

TORONTO, ONTARIO-May 18, 2011-Novadaq® Technologies Inc. (TSX: NDQ), a developer of real-time medical imaging systems for use in the operating room, today announced that it has appointed Dr. David C. Martin as Vice President, Business Development and Investor Relations. Prior to joining…
May 17, 2011 - OncoGenex to Present at the UBS Global Specialty Pharmaceuticals Conference

BOTHELL, WA, and VANCOUVER - May 17, 2011 - OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) announced today that Cameron Lawrence, OncoGenex' Director of Finance and Principal Accounting Officer, will be presenting at the UBS Global Specialty Pharmaceuticals Conference on Wednesday,…
May 12, 2011 - Tranzyme Pharma Announces First Quarter 2011 Financial Results

RESEARCH TRIANGLE PARK, NC - May 12, 2011 - Tranzyme Pharma (Nasdaq:TZYM), a clinical‑stage biopharmaceutical company focused on discovering, developing and commercializing novel, first-in-class small molecule therapeutics for the treatment of acute (hospital‑based) and chronic…
May 12, 2011 - Novadaq Reports First Quarter 2011 Financial Results

TORONTO, ONTARIO -May 12, 2011 - Novadaq® Technologies Inc. (TSX: NDQ), a developer of real-time medical imaging systems for use in the operating room, today announced its financial results for the first quarter ended March 31, 2011. Unless otherwise indicated, all dollar amounts in…
May 11, 2011 - Novadaq Technologies Inc. Notice of Annual and Special Shareholder Meeting

TORONTO, ONTARIO -May 11, 2011 - Novadaq® Technologies (TSX: NDQ), a developer of real-time, medical imaging systems for use in the operating room, announced today that it will be holding its Annual and Special Shareholder Meeting hosted by Dr. Arun Menawat, President and Chief Executive…
May 10, 2011 - Tranzyme Pharma to Present Additional Phase 2 Data of Oral GI Motility Agent TZP-102 Showing Improvement of Debilitating Symptoms in Patients with Diabetic Gastroparesis

CHICAGO, IL - May 10, 2011 - Tranzyme Pharma (Nasdaq:TZYM), a clinical-stage biopharmaceutical company, will present Phase 2 data of TZP-102, an orally-administered ghrelin agonist in development for diabetic gastroparesis, an upper gastrointestinal (GI) motility disorder, during a…
May 9, 2011 - OncoGenex Pharmaceuticals, Inc. Reports Financial Results for First Quarter 2011 and Provides Update on Plans for the Phase 3 Prostate Cancer SATURN Clinical Trial

BOTHELL, WA and VANCOUVER, BC - May 9, 2011 - OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) today announced its first quarter financial results and provided an update on current events and activities. Key OncoGenex Activities Currently enrolling the Phase 3 clinical…
May 5, 2011 - Tranzyme Pharma Announces Partial Exercise of Over-Allotment Option for Initial Public Offering

RESEARCH TRIANGLE PARK, NC - May 5, 2011 - Tranzyme Pharma (Nasdaq:TZYM), today announced that the underwriters of its recently completed initial public offering (IPO) have partially exercised their option to purchase shares of common stock from Tranzyme to cover over-allotments. The…
May 3, 2011 - Tranzyme Pharma to Report First Quarter 2011 Financial Results

RESEARCH TRIANGLE PARK, NC - May 3, 2011 - Tranzyme Pharma (Nasdaq:TZYM), today announced that it will host a conference call on Friday, May 13, 2011 at 8:30 A.M. ET to discuss first quarter 2011 financial results. The Company will report first quarter 2011 financial results after the…
May 2, 2011 - OncoGenex to Webcast Discussion of First Quarter Financial Results on Monday, May 9, 2011

BOTHELL, WA and VANCOUVER - May 2, 2011 - OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) announced that the Company's first quarter 2011 financial results will be released on Monday, May 9, 2011 after the NASDAQ Global Market closes at 4:00 p.m. ET, and that the Company will host a…
April 29, 2011 - Novadaq to Release Fiscal Q1-11 Financial Results on May 12 – Conference Call to Follow

TORONTO, ONTARIO -April 29, 2011-Novadaq® Technologies Inc. (TSX: NDQ), a developer of real-time medical imaging systems for use in the operating room, will announce its first quarter 2011 financial results prior to the market opening on Thursday, May 12, 2011. Novadaq is pleased to…
April 15, 2011 - New Class of Flexible Instruments from Apollo Endosurgery® Used for Endoluminal Removal of Gastric Tumor

Austin, TX - April 15, 2011 - Florida Hospital Celebration Health announced this week the use of a new class of flexible surgical instruments created by Apollo Endosurgery®, to remove a stomach tumor and extract it through the patient’s mouth. Following the two-hour surgery, the…
April 14, 2011 - OncoGenex Pharmaceuticals Announces Issuance of Key European Patent for OGX-427

BOTHELL, Wash. and VANCOUVER, British Columbia - April 14, 2011 - OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI), today announced that the European Patent Office (EPO) has granted European Patent Number EP1545561 entitled "Oligonucleotides for Treatment of Prostate and other Cancers."…
April 6, 2011 - Teva and OncoGenex Present Preclinical Data on the Activity of its Antisense Compound Custirsen (OGX-011/TV-1011) at the American Association of Cancer Research (AACR) Annual Meeting 2011

JERUSALEM, Israel & BOTHELL, Wash. & VANCOUVER, British Columbia - April 6, 2011 - Teva Pharmaceutical Industries Ltd. (NASDAQ:TEVA) and OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) announced today that new preclinical data of their investigational compound custirsen (OGX-011/TV-1011)…
April 4, 2011 - OncoGenex Announces Data Highlighting OGX-427 at American Association of Cancer Research (AACR) 102nd Annual Meeting 2011

BOTHELL, Wash. and VANCOUVER, British Columbia - April 4, 2011 - OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) announced today that preclinical data utilizing their pipeline compound OGX-427 was presented at the AACR 102nd Annual Meeting 2011. The study demonstrated the ability of…
April 1, 2011 - Tranzyme Pharma Announces Pricing of Its Initial Public Offering

RESEARCH TRIANGLE PARK, N.C. - April 1, 2011 - Tranzyme Pharma (Nasdaq:TZYM) announced today the pricing of its initial public offering of 13,500,000 shares of its common stock at $4.00 per share. The shares are expected to begin trading on Monday, April 4, 2011 on The NASDAQ Global…
March 29, 2011 - OncoGenex to Present at the Needham & Company 10th Annual Healthcare Conference

BOTHELL, Wash. and VANCOUVER, British Columbia - March 29, 2011 - OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) announced today that Scott Cormack, OncoGenex' president and chief executive officer, will provide a corporate presentation at the Needham & Company 10th Annual Healthcare…
March 28, 2011 - Novadaq Reports Fiscal 2010 Full-Year and Fourth Quarter Financial Results

Toronto, Ontario - March 28, 2011 - Novadaq® Technologies Inc. (TSX: NDQ), a developer of real-time medical imaging systems for use in the operating room, today announced its financial results for the fiscal year and fourth quarter ended December 31, 2010. Unless otherwise indicated,…
March 25, 2011 - Novadaq Completes Private Placement Offering of Units

Toronto, Ontario - March 25, 2011 - Novadaq® Technologies Inc. (TSX: NDQ), a developer of real‐time medical imaging systems for use in the operating room, announced today that on March 24, 2011 it closed its previously announced private placement of 4,731,864 units at a price of…
March 22, 2011 - Novadaq to Present at the 10th Annual Needham Healthcare Conference

Toronto, Ontario - March 22, 2011 - Novadaq® Technologies Inc. (TSX: NDQ), a developer of real-time medical imaging systems for use in the operating room, today announced that Dr. Arun Menawat, the Company’s President and Chief Executive Officer, will present at the 10th Annual Needham…
March 21, 2011 - Novadaq to Release Fiscal 2010 Year-End and Q4-10 Financial Results on March 28 – Conference Call to Follow

Toronto, Ontario - March 21, 2011 - Novadaq® Technologies Inc. (TSX: NDQ), a developer of real-time medical imaging systems for use in the operating room, will announce its fiscal 2010 year-end and fourth quarter 2010 financial results prior to the market opening on Monday, March 28,…
March 18, 2011 - Novadaq Announces Private Placement Offering of Units

Toronto, Ontario - March 18, 2011 - Novadaq® Technologies Inc. (TSX: NDQ), a developer of real-time medical imaging systems for use in the operating room, announced today that it has entered into subscription agreements pursuant to which it will raise approximately $15,000,000 though…
March 10, 2011 - OncoGenex Pharmaceuticals, Inc. Reports Financial Results for Fourth Quarter and Year End 2010 and Provides Update on Custirsen Clinical Development Program

BOTHELL, Wash. and VANCOUVER, British Columbia - March 10, 2011 -OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) today announced its fourth quarter and year end 2010 financial results, reviewed updates to the Company's development programs and provided an outlook for 2011. "Over the…
March 7, 2011 - OncoGenex to Webcast Discussion of Fourth Quarter and Full Year 2010 Financial Results on Thursday, March 10, 2011

BOTHELL, Wash. and VANCOUVER, British Columbia - March 7, 2011 -OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) announced today that the Company's fourth quarter and full year 2010 financial results will be released on Thursday, March 10, 2011 after the NASDAQ Global Market closes at…
March 4, 2011 - Tranzyme Pharma Appoints Financial and Pharmaceutical Leader Anne M. VanLent to its Board of Directors

RESEARCH TRIANGLE PARK, N.C. - March 4, 2011 - Tranzyme Pharma today announced the appointment of Anne M. VanLent to its Board of Directors and to serve on and Chair the Company’s Audit Committee. Ms. VanLent is currently President of AMV Advisors, a company she founded in 2008 to…
February 28, 2011 - OncoGenex Pharmaceuticals to Participate in Panel Discussion on Novel Cancer Treatments at RBC Capital Markets Healthcare Conference

BOTHELL, WA and VANCOUVER - February 28, 2011 - PRNewswire/ -- OncoGenex Pharmaceuticals, Inc. (Nasdaq: OGXI) announced today that Scott Cormack, OncoGenex's president and chief executive officer, will take part in a panel discussion on novel cancer treatments at the upcoming RBC Capital…
February 23, 2011 - Tranzyme Pharma and Norgine Initiate Dosing in Phase 3 Pivotal Study of Novel Intravenous GI Motility Drug Ulimorelin

RESEARCH TRIANGLE PARK, NC and AMSTERDAM, NETHERLANDS - February 23, 2011 - Tranzyme Pharma and Norgine B.V., have initiated dosing of ulimorelin in the first of two, Phase 3 pivotal studies - ULISES (ULImorelin Safety and Efficacy…
February 17, 2011 - OncoGenex Included in Fast Company Magazine's Top Ten "Most Innovative Companies" in the Biotech Industry

BOTHELL, WA and VANCOUVER - February 17, 2011 - PRNewswire/ - OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) has been named as one of the top ten companies in the biotech industry in the March 2011 issue of Fast Company, as part of the magazine's annual list of the "Most Innovative…
February 8, 2011 - OncoGenex Pharmaceuticals to Present at the 13th Annual BIO CEO & Investor Conference

BOTHELL, WA, and VANCOUVER - February 8, 2011 - PRNewswire/ - OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) announced today that Scott Cormack, OncoGenex's president and chief executive officer, will provide a corporate presentation at the 13th Annual BIO CEO & Investor Conference…
February 2, 2011 - Novadaq Completes Purchase of TMR Business from PLC Systems

TORONTO, ONTARIO - February 2, 2011 - Novadaq® Technologies Inc. (TSX: NDQ), a developer of real-time medical imaging systems for use in the operating room, today announced that it has completed the purchase of the Transmyocardial Revascularization (TMR) business from PLC Systems Inc.…
January 19, 2011 - Two Laser Balloon “Live Cases” Shed New Light on Direct Visualization and PV Ablation

MARLBOROUGH, MA - January 19, 2011 - CardioFocus announced today that two “live cases” using its Endoscopic Ablation System were recently conducted. The first live case was a satellite transmission performed at Centro Cardiologico Monzino in Milan, Italy and broadcast to the 16th…
January 4, 2011 - Novadaq to Present at January Investor Conferences

TORONTO, ONTARIO - January 4, 2011 - Novadaq® Technologies Inc. (TSX: NDQ), a developer of real-time medical imaging systems for use in the operating room, today announced that Company Management will present at the following two investor conferences: 2011 OneMedForum on Tuesday, January…
January 1, 2011 - Apollo Endosurgery Demonstrates Clinical Functionality of the Newly Launched OverStitch™ Endoscopic Suturing System in Bariatric Repairs and GI Therapy

AUSTIN, TX - January 01, 2011 - Apollo Endosurgery, Inc. announced preliminary results from their GEMINI suturing registry. These results confirm the procedure enabling capability of their newly-launched OverStitch™ Endoscopic Suturing System in a variety of clinical cases in the…
December 20, 2010 - Quinnova Pharmaceuticals, Inc. Joins the Amneal Enterprises, LLC Alliance

BRIDGEWATER, NJ - December 20, 2010 - Amneal Enterprises, LLC, an alliance of life science companies, is pleased to announce the addition of Quinnova Pharmaceuticals, Inc., Newtown, PA, as an independent affiliate of Amneal Enterprises, LLC via its acquisition by AmDerma Pharmaceuticals,…
December 15, 2010 - Tranzyme Pharma Appoints Pharmaceutical Industry Veteran John H. Johnson as Chairman of its Board of Directors

RESEARCH TRIANGLE PARK, NC - December 15, 2010 - Tranzyme Pharma today announced the appointment of John H. Johnson as Chairman of its Board of Directors. Mr. Johnson currently serves as President, Lilly Oncology and Senior Vice President, Eli Lilly and Company. ”I am extremely pleased…
November 22, 2010 - OncoGenex Pharmaceuticals to Present at the Piper Jaffray 22nd Annual "Unplugged" Health Care Conference

BOTHELL, WA and VANCOUVER - November 22, 2010 - OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) announced today that Scott Cormack, president and chief executive officer of OncoGenex, will present at the Piper Jaffray 22nd Annual "Unplugged" Health Care Conference on Tuesday, November…
November 10, 2010 - Novadaq Reports Third Quarter 2010 Financial Results

TORONTO, ONTARIO-November 10, 2010 - Novadaq® Technologies Inc. (TSX: NDQ), a developer of real-time medical imaging systems for use in the operating room, today announced 2010 third quarter revenues of $7,570,000 compared to revenues of $1,723,000 in the third quarter of 2009 and…
November 9, 2010 - NeurAxon, Inc. to Present at Lazard Capital Markets 7th Annual Healthcare Conference November 16, 2010

WALTHAM, MA - November 9, 2010 - NeurAxon, Inc. is pleased to announce that Lawrence Bloch, M.D., J.D., the Company’s Chief Executive Officer, will present at the Lazard Capital Markets 7th Annual Healthcare Conference taking place November 16-17, 2010 in New York City. The NeurAxon…
November 8, 2010 - OncoGenex Pharmaceuticals Names Michelle Burris Executive Vice President, Operations and Chief Financial Officer

BOTHELL, WA and VANCOUVER - November 8, 2010 - PRNewswire-FirstCall/ - OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) today announced the appointment of Michelle Burris to the position of executive vice president, operations and chief financial officer. Ms. Burris, a seasoned public…
November 8, 2010 - Novadaq Enters Into Asset Purchase Agreement with PLC Systems for TMR

TORONTO, ONTARIO-November 8, 2010-Novadaq® Technologies Inc. (TSX: NDQ), a developer of real-time imaging systems for use in the operating room, announced today that it has entered into a definitive asset purchase agreement with PLC Systems Inc. (“PLC”) for the CO2 Heart Laser™…
November 4, 2010 - OncoGenex Reports Third Quarter Financial Results

BOTHELL, WA and VANCOUVER - November 4, 2010 - PRNewswire-FirstCall/ - OncoGenex Pharmaceuticals, Inc. ("OncoGenex" or the "Company") (NASDAQ: OGXI) today reported unaudited financial results for the three and nine months ended September 30, 2010 and provided an update on the business,…
November 3, 2010 - Novadaq CEO to Present on SPY Imaging at November Investor Conferences

TORONTO, ONTARIO-November 3, 2010- Novadaq® Technologies Inc. (TSX: NDQ), a developer of real-time medical imaging systems for use in the operating room, announced today Dr. Arun Menawat, Chief Executive Officer, will present at the following investor conferences during November: ·…
November 1, 2010 - Apollo Endosurgery Completes First-in-Human Cases with New OverStitch™ Endoscopic Suturing System

AUSTIN, TX - November 1, 2010 - Apollo Endosurgery, Inc. announced that their newly launched OverStitch™ Endoscopic Suturing System has recently been employed in several, first-in-human cases. OverStitch Endoscopic Suturing System is a unique device that mimics the way physicians…
October 31, 2010 - NeurAxon Announces NXN-188 Phase 2 Data Demonstrating Efficacy in Acute Migraine

WALTHAM, MA - October 31, 2010 - NeurAxon, Inc., announced today Phase 2 clinical study results for NXN-188, a novel, first-in-class treatment with the potential to raise the current standard of care in acute migraine. NXN-188 is a dual action new chemical entity which incorporates…
October 27, 2010 - Novadaq to Release Q3-10 Financial Results on November 10 – Conference Call to Follow

TORONTO, ONTARIO-October 27, 2010 - Novadaq® Technologies Inc. (TSX: NDQ), a developer of real-time medical imaging systems for use in the operating room, will announce its third quarter 2010 financial results prior to the market opening on Wednesday, November 10, 2010. Novadaq is…
October 26, 2010 - NeurAxon's NXN-188 Named One of 10 Most Promising Neuroscience Projects by Windhover

WALTHAM, MA - October 26, 2010 - NeurAxon, Inc., a development-stage pharmaceutical company that is designing and developing next-generation pain therapeutics targeting neuronal nitric oxide synthase (nNOS), today announced that NXN-188, a novel oral selective nitric oxide synthase…
October 22, 2010 - OncoGenex Pharmaceuticals, Inc. Closes $50 Million Public Offering

BOTHELL, WA, and VANCOUVER - October 22, 2010 - (Canada NewsWire via COMTEX News Network) - OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) today announced that it has completed a public offering of 3,174,602 units at a price to the public of $15.75 per unit for an aggregate offering…
October 21, 2010 - OncoGenex to Webcast Third Quarter Financial Results on Thursday, November 4, 2010

BOTHELL, WA and VANCOUVER - October 21, 2010 - (Canada NewsWire via COMTEX News Network) - OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) announced today that the Company's third quarter financial results will be released on Thursday, November 4, 2010, and that the Company will host…
October 19, 2010 - OncoGenex Pharmaceuticals, Inc. Prices $50 Million Public Offering

BOTHELL, WA, and VANCOUVER - October 19, 2010 - (Canada NewsWire via COMTEX News Network) - OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) today announced that it has priced a public offering of 3,174,602 units, with each unit consisting of one share of the Company's common stock and…
October 18, 2010 - OncoGenex Pharmaceuticals, Inc. Announces Proposed Public Offering

BOTHELL, WA and VANCOUVER - October 18, 2010 - (Canada NewsWire via COMTEX News Network) - OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) today announced that it is commencing a public offering of its common stock and warrants to purchase shares of its common stock. OncoGenex intends…
October 14, 2010 - NeurAxon Named One of Canada's Top 10™ Life Science Companies

TORONTO, ON - October 14, 2010 - NeurAxon, Inc., a development-stage pharmaceutical company that is designing and developing next-generation pain therapeutics targeting neuronal nitric oxide synthase (nNOS), has been named as one of Canada’s Top 10™ Life Science Companies and was…
October 7, 2010 - Apollo Endosurgery Completes First Clinical Case with Newly-Launched FlexShears™ Endoscopic Scissors

AUSTIN, TX- October 7, 2010 - Apollo Endosurgery, Inc. announced completion of the first clinical case involving its FlexShears™ Endoscopic Scissors. The new device was used to cut and remove an obstructing eroded suture from the patient’s GI tract in a procedure that embodies the…
October 4, 2010 - OncoGenex Pharmaceuticals to Present at the 9th Annual BIO Investor Forum

BOTHELL, WA and VANCOUVER - October 4, 2010 - (Canada NewsWire via COMTEX News Network) - OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) announced today that management of OncoGenex will present at the 9th Annual BIO Investor Forum on Wednesday, October 6 at 10:30 a.m. PDT at The Palace…
October 1, 2010 - Apollo Endosurgery Completes First-in-Human Cases with New OverStitch™ Endoscopic Suturing System

AUSTIN, TX - October 1, 2010 - Apollo Endosurgery, Inc. announced that their newlylaunched OverStitch™ Endoscopic Suturing System has recently been employed in several, first-in-human cases. OverStitch Endoscopic Suturing System is a unique device that mimics the way physicians deploy…
September 30, 2010 - Teva and OncoGenex Announce Initiation of Second Phase 3 Trial of Custirsen in Men with Metastatic Prostate Cancer

JERUSALEM, BOTHELL, WA and VANCOUVER, B.C. - September 30, 2010 - (BUSINESS WIRE) - Teva Pharmaceuticals Industries Ltd. (NASDAQ: TEVA) and OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) announced today the initiation of SYNERGY, a global Phase 3 trial evaluating custirsen (also known…
September 29, 2010 - NeurAxon Announces Closing of Convertible Debenture Financing

TORONTO, ON- September 29, 2010 - NeurAxon, Inc., a development-stage pharmaceutical company that is designing and developing next-generation pain therapeutics targeting neuronal nitric oxide synthase (nNOS), today announced that it has closed a convertible debenture financing in which…
September 28, 2010 - NeurAxon, Inc. to Present at Upcoming Investor and Business Development Conferences

WALTHAM, MA- September 28, 2010 - NeurAxon, Inc. is pleased to announce that Lawrence Bloch, M.D., J.D., the Company’s Chief Executive Officer, will participate in the following conferences: The Sachs 10th Annual Biotech in Europe Investor Forum, September 29 - 30, 2010 at the Radisson…
September 27, 2010 - OncoGenex Pharmaceuticals Announces Initiation of a Phase 2 Trial Evaluating OGX-427 Treatment in Men with Advanced Prostate Cancer

BOTHELL, WA and VANCOUVER - September 27, 2010 - (Canada NewsWire via COMTEX News Network) - OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) announced today the initiation of a randomized, controlled, investigator-sponsored Phase 2 trial of OGX-427 in men with metastatic prostate cancer.…
September 22, 2010 - OncoGenex Pharmaceuticals, Inc.-Journal of Clinical Oncology Publishes Data from Randomized Phase 2 Custirsen Trial

BOTHELL, WA and VANCOUVER - September 22, 2010 - (Canada NewsWire via COMTEX News Network) -- Randomized Phase 2 Study of Docetaxel and Prednisone With or Without OGX-011 in Patients With Metastatic Castration-Resistant Prostate Cancer. Chi K.N., et al. JCO Sep 20, 2010: 4247-4254.…
September 15, 2010 - FierceBiotech Designates Alder Biopharmaceuticals One of Top Private Biotechs, Member of the 2010 Fierce 15

BOTHELL, WA- September 15, 2010 - Alder Biopharmaceuticals Inc. today announced FierceBiotech has designated it one of the top private biotech companies and placed it on the annual Fierce 15. The list, published annually by FierceBiotech, highlights 15 of the top privately held biotech…
September 13, 2010 - Novadaq CEO to Present on SPY Imaging at September Investor Conferences

TORONTO, ONTARIO - September 13, 2010 - Novadaq® Technologies Inc. (TSX: NDQ), a developer of real-time imaging systems for use in the operating room, announced today Dr. Arun Menawat, Chief Executive Officer, will present at the following investor conferences during…
September 7, 2010 - OncoGenex Pharmaceuticals to Present at the Stifel Nicolaus Healthcare Conference and the UBS Global Life Sciences Conference

BOTHELL, WA and VANCOUVER - September 7, 2010 - (Canada NewsWire via COMTEX News Network) - OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) announced today that Scott Cormack, president and chief executive officer of OncoGenex, will present at the Stifel Nicolaus Healthcare Conference…
September 1, 2010 - KCI's LifeCell™ Corporation and Novadaq Technologies Enter North American Sales and Marketing Agreement for Exclusive Distribution of SPY® Imaging System

SAN ANTONIO, TX - September 1, 2010 - LifeCell™ Corporation, a business unit of Kinetic Concepts, Inc. (NYSE: KCI), and Novadaq® Technologies Inc. (TSX: NDQ) announced today the signing of an exclusive sales and marketing agreement for distribution of Novadaq’s SPY® Imaging System…
September 1, 2010 - Novadaq Signs North American Marketing and Sales Agreement with LifeCell

TORONTO, ONTARIO - September 1, 2010 - Novadaq® Technologies Inc. (TSX: NDQ), a developer of real-time imaging systems for use in the operating room, announced today that it has entered into a five-year agreement with LifeCell™ Corporation for exclusive rights to market and distribute…
August 25, 2010 - Tranzyme Pharma to Present Ulimorelin Data Showing Reduction in Daily Vomiting in Patients with Diabetic Gastroparesis

RESEARCH TRIANGLE PARK, NC - August 25, 2010 - Tranzyme Pharma announced today that John Wo, MD, Professor of Medicine, Director, Clinical Research, Division of Gastroenterology, Hepatology and Nutrition, University of Louisville, Louisville, KY, will present ulimorelin Phase 2 data…
August 23, 2010 - Novadaq Achieves Final Milestone in Intuitive Development Agreement

TORONTO, ONTARIO - August 23, 2010 - Novadaq®Technologies Inc. (TSX: NDQ), a developer of real-time imaging systems for use in the operating room, announced today that it has completed the final design review for the integration of the company’s SPY®imaging technology into the 3-D…
August 17, 2010 - Joel I. Shalowitz, M.D., Appointed to Novadaq Board of Directors

TORONTO, ONTARIO - August 17, 2010 - Novadaq® Technologies Inc. (TSX: NDQ), a developer of real-time imaging systems for use in the operating room, today announced that Joel I. Shalowitz, M.D., MBA FACP, has been appointed to the company’s Board of Directors. Dr. Shalowitz is Professor…
August 12, 2010 - Novadaq Reports Second Quarter 2010 Financial Results

TORONTO, ONTARIO - August 12, 2010 - Novadaq® Technologies Inc. (TSX: NDQ), a developer of real-time imaging systems for use in the operating room, today announced 2010 second quarter revenues of $2,647,000 compared to revenues of $1,699,000 in second quarter 2009. Sales of SPY products…
August 10, 2010 - OncoGenex Adds David V. Smith to the Board of Directors

BOTHELL, WA and VANCOUVER, BC - August 10, 2010 - (Canada NewsWire via COMTEX News Network) - OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI), announced today that the Company has appointed Mr. David V. Smith to its board of directors. Mr. Smith brings to the board substantial financial…
August 5, 2010 - OncoGenex Reports Second Quarter Financial Results

BOTHELL, WA and VANCOUVER, BC - August 5, 2010 - (Canada NewsWire via COMTEX News Network) - Conference Call on Thursday, August 5, 2010 at 4:30 p.m. Eastern Time OncoGenex Pharmaceuticals, Inc. ("OncoGenex" or the "Company") (NASDAQ: OGXI) today reported unaudited financial results…
August 4, 2010 - Gemin X Closes $8 Million Series E Financing

MALVERN, PA and MONTRÉAL, QC - August 04, 2010 - Gemin X Pharmaceuticals, a clinical stage biopharmaceutical company developing novel, targeted cancer therapeutics, today announced the completion of its $8 million Series E round of financing. All of the company's preferred stockholders…
July 29, 2010 - OncoGenex to Webcast Second Quarter Financial Results on Thursday, August 5, 2010

BOTHELL, WA and VANCOUVER, BC - July 29, 2010 - (Canada NewsWire via COMTEX News Network) - OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) announced today that the Company's second quarter financial results will be released on Thursday, August 5, 2010, and that the Company will host…
July 29, 2010 - NeurAxon, Inc. to Present at BMO Capital Markets 10th Annual Focus on Healthcare Conference August 5, 2010

WALTHAM, MA - July 29, 2010 - NeurAxon, Inc. is pleased to announce that Lawrence Bloch, M.D., J.D., the Company’s Chief Executive Officer, will present at the BMO Capital Markets 10th Annual Focus on Healthcare Conference taking place August 5, 2010 in New York City. The NeurAxon…
July 26, 2010 - Novadaq to Release Q2-10 Financial Results on August 12 – Conference Call to Follow

TORONTO, ONTARIO - July 26, 2010 - Novadaq® Technologies Inc. (TSX: NDQ), a developer of real-time medical imaging systems for the operating room, will announce its second quarter 2010 financial results prior to the market opening on Thursday, August 12, 2010. Novadaq is pleased to…
June 29, 2010 - Tranzyme Pharma Announces Positive Results from Phase 2 Study of Oral TZP-102 (Ghrelin Agonist) in Patients with Diabetic Gastroparesis

RESEARCH TRIANGLE PARK, NC - June 29, 2010 - Tranzyme Pharma announced positive top-line results today from a Phase 2, double-blind, placebo-controlled study evaluating TZP-102 capsules in diabetic patients with gastroparesis, a serious disorder characterized by the inability of the…
June 22, 2010 - Apollo Endosurgery recommended for $5 million Commercialization Award from the Cancer Prevention and Research Institute of Texas

AUSTIN, TX - June 22, 2010 - Apollo Endosurgery announced today that the Company received notice of a $5 million award from the State of Texas through the Cancer Prevention and Research Institute of Texas (“CPRIT”). Apollo was one of only three companies recommended for the inaugural…
June 21, 2010 - OncoGenex Pharmaceuticals Announces Initiation of a Phase 3 Trial in Men with Metastatic Prostate Cancer

BOTHELL, WA and VANCOUVER, BC - June 21, 2010 - (Canada NewsWire via COMTEX News Network) - OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) announced today the initiation of a Phase 3 registration trial of custirsen sodium (OGX011/TV-1011), its lead product candidate being developed…
June 16, 2010 - New Data for Investigational Antibody Blocking IL-6 in Rheumatoid Arthritis Patients to be Presented at Annual Congress of European League Against Rheumatism

ROME - June 16, 2010 - Bristol-Myers Squibb Company (NYSE:BMY) and Alder Biopharmaceuticals today announced that new data from a dose-ranging Phase 2a trial support further development of BMS-945429/ALD518, an investigational monoclonal antibody directed against interleukin-6 (IL-6),…
June 16, 2010 - Tranzyme Pharma and Norgine Sign License Agreement for Late-Stage Development Product, Ulimorelin (TZP-101), in Europe and Other Select Regions

RESEARCH TRIANGLE PARK, NC and AMSTERDAM, NETHERLANDS - June 16, 2010 - Tranzyme Pharma, a clinical-stage biopharmaceutical company, and Norgine B.V., a European specialty pharmaceutical company, announced today that they have entered into a licensing agreement that provides Norgine…
June 16, 2010 - New Data for Investigational Antibody Blocking IL-6 in Rheumatoid Arthritis Patients to be Presented at Annual Congress of European League Against Rheumatism

ROME - June 16, 2010 - Bristol-Myers Squibb Company (NYSE:BMY) and Alder Biopharmaceuticals today announced that new data from a dose-ranging Phase 2a trial support further development of BMS-945429/ALD518, an investigational monoclonal antibody directed against interleukin-6 (IL-6),…
June 14, 2010 - HyperBranch Receives CE Mark for Adherus™ Spinal Sealant

DURHAM, NC - June 14, 2010 - HyperBranch Medical Technology, Inc. announced today that it has received a CE Mark for Adherus™ Spinal Sealant. Adherus™ Spinal Sealant is used in spinal surgeries where a water tight seal is required to prevent cerebrospinal fluid leakage from the…
June 7, 2010 - OncoGenex Pharmaceuticals Announces Final Results from Phase 1 Trial Evaluating OGX427 as a Treatment for Solid Tumors

BOTHELL, WA and VANCOUVER, BC - June 7, 2010 - (Canada NewsWire via COMTEX News Network) - Results Presented at ASCO 2010 Annual Meeting Confirm Acceptable Safety Profile and Evidence of Biological Activity Including Declines in Circulating Tumor Cells and Reductions in Tumor Markers…
June 7, 2010 - Alder Biopharmaceuticals to Present at Two Upcoming Investor Conferences

BOTHELL, WA - June 7, 2010 - Alder Biopharmaceuticals Inc., announced today that Randall Schatzman, Ph.D., president and chief executive officer, will present at the Jefferies Global Life Sciences Conference and Needham Healthcare Conference in New York City. The presentation at the…
June 7, 2010 - Novadaq to Present on SPY Imaging at Needham Healthcare Conference

TORONTO, ONTARIO - June 7, 2010 - Novadaq® Technologies Inc. (TSX: NDQ), a developer of real-time imaging systems for use in the operating room, today announced Dr. Arun Menawat, Chief Executive Officer, will present a live webcast during the 9th Annual Needham Healthcare Conference…
June 6, 2010 - Alder Biopharmaceuticals' ALD518 Antibody Therapeutic Reduces Disease Symptoms, Anemia in Phase 2a Clinical Trial in Non-Small Cell Lung Cancer Patients

CHICAGO, IL - June 6, 2010 - Alder Biopharmaceuticals Inc. today announced that patients with late-stage non-small cell lung cancer (NSCLC) showed improvement in cancer-related anemia and symptoms of the disease in a Phase 2a clinical trial of ALD518, a monoclonal antibody directed…
June 3, 2010 - OncoGenex Pharmaceuticals to Present at the 9th Annual Needham Healthcare Conference

BOTHELL, WA and VANCOUVER, BC - June 3, 2010 - (Canada NewsWire via COMTEX News Network) - OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) announced today that Scott Cormack, OncoGenex's President and Chief Executive Officer, will present at the 9th Annual Needham Healthcare Conference…
June 2, 2010 - NeurAxon, Inc. to Present at 9th Annual Needham Healthcare Conference June 9, 2010

WALTHAM, MA - June 2, 2010 - NeurAxon, Inc. is pleased to announce that Lawrence Bloch, M.D., J.D., the Company’s Chief Executive Officer, will present at the 9th Annual Needham Healthcare Conference taking place June 9-10, 2010 in New York, NY. The NeurAxon presentation will be delivered…
May 18, 2010 - NeurAxon, Inc. to Make Multiple Presentations at the International Symposium on Nitric Oxide and Other Gaseous Neurotransmitters

WALTHAM, MA - May 18, 2010 - NeurAxon, Inc. today announced several scientific presentations by officers and advisors to the Company at the International Symposium on Nitric Oxide and Other Gaseous Neurotransmitters, May 27 - 28, 2010 in Toronto, Ontario. NeurAxon is focused on the…
May 13, 2010 - OncoGenex Pharmaceuticals to Present at the 6th Annual Rodman and Renshaw Global Healthcare Conference

BOTHELL, WA and VANCOUVER, BC - May 13, 2010 - (Canada NewsWire via COMTEX News Network) -OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) announced today that Scott Cormack, OncoGenex's President and Chief Executive Officer, will present at the 6th Annual Rodman and Renshaw Global Healthcare…
May 12, 2010 - Novadaq Reports First Quarter 2010 Financial Results

TORONTO, ONTARIO - May 12, 2010 - Novadaq® Technologies Inc. (TSX: NDQ), a developer of real-time imaging systems for use in the operating room, today announced 2010 first quarter revenues of $2,419,408 compared to revenue of $3,014,000 in first quarter 2009. Recurring revenues for…
May 6, 2010 - OncoGenex Reports First Quarter Financial Results

BOTHELL, WA and VANCOUVER, BC - May 6, 2010 - (Canada NewsWire via COMTEX News Network) - Conference Call on Thursday, May 6, 2010 at 4:30 p.m. Eastern Time OncoGenex Pharmaceuticals, Inc. ("OncoGenex" or the "Company") (NASDAQ: OGXI) today reported unaudited financial results for the…
April 29, 2010 - OncoGenex to Webcast First Quarter Financial Results on May 6, 2010

BOTHELL, WA and VANCOUVER, BC - April 29, 2010 - (Canada NewsWire via COMTEX News Network) - OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) announced today that the Company's first quarter financial results will be released on Thursday May 6, 2010, and that the Company will host a conference…
April 28, 2010 - Novadaq to Release Q1-10 Financial Results on May 12 – Conference Call to Follow

TORONTO, ONTARIO - April 28, 2010 - Novadaq® Technologies Inc. (TSX: NDQ), a developer of real-time medical imaging systems for the operating room, will announce its first quarter 2010 financial results prior to the market opening on Wednesday, May 12. Novadaq is pleased to invite…
April 22, 2010 - Novadaq Technologies Notice of Annual Meeting

TORONTO, ONTARIO - April 22, 2010 - Novadaq® Technologies Inc. (TSX: NDQ), a developer of real-time medical imaging systems for use in the operating room, will be holding its annual meeting, hosted by Dr. Arun Menawat, President and Chief Executive Officer and Mr. Stephen Purcell,…
April 20, 2010 - Gemin X Announces $16 Million Series D Financing

MALVERN, PA and MONTRÉAL, QC - April 20, 2010 - Gemin X Pharmaceuticals, a clinical stage biopharmaceutical company developing novel, targeted cancer therapeutics, today announced the close of its $16 million Series D round of financing. Current investors Caxton Advantage Life Sciences…
April 8, 2010 - OncoGenex Pharmaceuticals Awarded BIOTECanada's Biotech Company of the Year Award

BOTHELL, WA and VANCOUVER, BC - April 8, 2010 - (Canada NewsWire via COMTEX News Network) - OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) announced today that the Company will be presented with BIOTECanada's Gold Leaf Award as biotech company of the year. The award recognizes a biotech…
March 30, 2010 - Novadaq Reports Fiscal 2009 Full-Year and Fourth Quarter Financial Results

TORONTO, ONTARIO - March 30, 2010 - Novadaq® Technologies Inc. (TSX: NDQ), a developer of real-time medical imaging systems for use in the operating room, today announced its financial results for the fiscal year and fourth quarter ended December 31, 2009. Unless otherwise indicated,…
March 29, 2010 - Gemin X Completes Patient Enrollment in Phase 2 Clinical Study of Obatoclax for First-Line Treatment of Small Cell Lung Cancer

MALVERN, PA and MONTRÉAL, QC - March 29, 2010 - Gemin X Pharmaceuticals, a clinical stage biopharmaceutical company developing novel, targeted cancer therapeutics, today announced the completion of patient enrollment in a Phase 2 clinical trial of the Company's lead product candidate…
March 25, 2010 - Data from OncoGenex Pharmaceuticals' Product Candidate OGX-427 to be Presented at the American Society of Clinical Oncology Annual Meeting

BOTHELL, WA and VANCOUVER, BC - March 25, 2010 - (Canada NewsWire via COMTEX News Network) - OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) announced today that final results from a Phase 1 study evaluating OncoGenex' product candidate, OGX-427, will be presented as part of the Scientific…
March 24, 2010 - OncoGenex Adds Biopharmaceutical Industry Veterans to the Board of Directors

BOTHELL, WA and VANCOUVER, BC - March 24, 2010 - (Canada NewsWire via COMTEX News Network) - OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI), announced today that the Company has appointed Dr. Jack Goldstein and Ms. H. Stewart Parker to its board of directors. In addition, Dr. Martin…
March 24, 2010 - Novadaq Receives Second Development Milestone Payment from Intuitive

TORONTO, ONTARIO - March 24, 2010 - Novadaq® Technologies Inc. (TSX: NDQ), a developer of real-time medical imaging systems for use in the operating room, announced today that it has received a $1,000,000 payment from Intuitive Surgical®, Inc. (NASDAQ:ISRG) for achieving the second…
March 16, 2010 - Novadaq to Release Fiscal 2009 Year-End and Q4-09 Financial Results on March 30 – Conference Call to Follow

TORONTO, ONTARIO - March 16, 2010 - Novadaq® Technologies Inc. (TSX: NDQ), a developer of real-time medical imaging systems for the operating room, will announce its fiscal 2009 year-end and fourth quarter 2009 results prior to the market opening Tuesday, March 30, 2010. Novadaq is…
March 15, 2010 - Peer-reviewed Research Elucidates Function of Hsp27; Supports OGX-427 Approach Targeting Cancer Treatment Resistance

BOTHELL, WA and VANCOUVER, BC - March 15, 2010 - (Canada NewsWire via COMTEX News Network) - OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI), announced today that two peer-reviewed manuscripts have been published that provide additional insight into the function of Heat Shock Protein…
March 10, 2010 - Nuseal Brand Becomes Adherus

DURHAM, NC - March 10, 2010 - HyperBranch Medical Technology, Inc. announced today that it will begin to market their surgical sealants under a new product identity - Adherus Surgical Sealants. The Adherus name will soon appear on all Company literature but the total transition in the…
March 8, 2010 - OncoGenex Reports Financial Results for Fourth Quarter and Fiscal Year 2009 and Provides Outlook for 2010

BOTHELL, WA and VANCOUVER, BC - March 8, 2010 - (Canada NewsWire via COMTEX News Network) -Conference Call on Monday, March 8, 2010 at 4:30 p.m. Eastern Time OncoGenex Pharmaceuticals, Inc. ("OncoGenex" or the "Company") (NASDAQ: OGXI), today announced its fourth quarter and fiscal…
March 4, 2010 - OncoGenex Pharmaceuticals to Webcast Discussion of Financial Results for Fourth Quarter and Fiscal Year 2009

BOTHELL, WA and VANCOUVER, BC - March 4, 2010 - (Canada NewsWire via COMTEX News Network) - OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) announced today that the Company's fourth quarter and fiscal year 2009 financial results will be released at the market close on Monday, March 8,…
March 1, 2010 - Peer-reviewed Articles Further Define Clusterin and the Role of a Clusterin Inhibitor, OGX011, for the Treatment of Cancer

BOTHELL, WA and VANCOUVER, BC - March 1, 2010 - (Canada NewsWire via COMTEX News Network) - OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI), announced today that two peer-reviewed articles have been published that further elucidate the biological function of clusterin, its role in promoting…
February 25, 2010 - The European Medicines Agency is in Overall Agreement with OncoGenex Pharmaceuticals' Development Plan for OGX-011 in Patients with Metastatic Castrate-Resistant Prostate Cancer

BOTHELL, WA and VANCOUVER, BC - February 25, 2010 - (Canada NewsWire via COMTEX News Network) - OncoGenex Pharmaceuticals (NASDAQ: OGXI) announced today that it has received written, scientific advice from the European Medicines Agency (EMA) on the company's development plan for OGX-011…
February 17, 2010 - Novadaq Announces Private Placement Offering of Units

TORONTO, ONTARIO - February 17, 2010 - Novadaq® Technologies Inc. (TSX: NDQ), a developer of real-time medical imaging systems for the operating room, is pleased to announce that it has entered into subscription agreements pursuant to which it will raise approximately $7,000,000 though…
January 11, 2010 - NeurAxon Awarded Grant from The Michael J. Fox Foundation to Research Novel Treatment Approach for Parkinson's Disease

WALTHAM, MA - January 11, 2010 - NeurAxon, Inc., a development-stage pharmaceutical company that is designing and developing next-generation pain therapeutics targeting neuronal nitric oxide synthase (nNOS), today announced that it has been awarded a grant of $267,000 from The Michael…
January 11, 2010 - Novadaq to Present on SPY Imaging at Needham Conference

TORONTO, ONTARIO - January 11, 2010 - Novadaq® Technologies Inc. (TSX: NDQ), a developer of real-time imaging systems for use in the operating room, today announced that Dr. Arun Menawat, President and Chief Executive Officer, will present at the 12th Annual Needham & Company,…
January 6, 2010 - OncoGenex Announces that a Randomized, Investigator-Sponsored Phase 2 Study Evaluating OGX-427 has Received Grant Funding

BOTHELL, WA and VANCOUVER, BC - January 6, 2010 - (Canada NewsWire via COMTEX News Network) - OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI), today announced that a randomized, controlled, investigator-sponsored Phase 2 clinical trial evaluating OGX-427 when administered as a monotherapy…
December 8, 2009 - Tranzyme Pharma Enters Into Strategic Drug Discovery Collaboration with Bristol-Myers Squibb

RESEARCH TRIANGLE PARK, NC - December 8, 2009 - Tranzyme Pharma today announced that it has entered into a strategic collaboration agreement with Bristol-Myers Squibb Company (NYSE: BMY) to discover, develop and commercialize novel macrocyclic compounds directed against targets of interest…
November 10, 2009 - Bristol-Myers Squibb and Alder Biopharmaceuticals Enter Global Agreement on Rheumatoid Arthritis Biologic

PRINCETON, NJ, and BOTHELL, WA - November 10, 2009 - Bristol-Myers Squibb Company (NYSE:BMY) and Alder Biopharmaceuticals, Inc., today announced a global agreement for the development and commercialization of ALD518, a novel biologic that has completed Phase IIa development for the…
October 28, 2009 - Safeguard Scientifics Leads $17.4 Million Series B Financing for Quinnova Pharmaceuticals

Wayne, PA - October 28, 2009 - Safeguard Scientifics, Inc. (NYSE: SFE), a holding company that builds value in growth-stage life sciences and technology companies, today announced it led a $17.4 million Series B financing round for Quinnova Pharmaceuticals, Inc., with participation…
October 13, 2009 - HyperBranch Receives CE Mark for NuSeal 30 Hernia Mesh Fixation Sealant

DURHAM, NC - October 13, 2009 - HyperBranch Medical Technology, Inc. announced today that it has received a CE Mark for its NuSeal 30 hernia mesh fixation sealant product. NuSeal 30 is used in hernia procedures to adhere the mesh. NuSeal 30 provides for secure mesh placement, minimizes…
September 9, 2009 - H.I.G. Ventures Invests $7 Million in Care Dynamix, Inc.

MIAMI, FL - September 9, 2009 - H.I.G. Ventures, LLC, the venture capital affiliate of H.I.G. Capital, today announced its $7 million growth capital investment in Care Dynamix (d/b/a FluBusters). Care Dynamix provides nationwide preventative healthcare services, including vaccination…
September 2, 2009 - Savvion Announces Event Lineup for BPMInstitute.org Brainstorm DC

SANTA CLARA, Calif. - September 2, 2009 - Savvion, the trailblazing business process management company, has announced its roster of activities related to its sponsorship of the BPMInstitute.org Brainstorm DC Conference Transparency and Accountability for an Open Government, September…
April 14, 2009 - Quinnova Pharmaceuticals, Inc. Receives FDA Clearance on Neosalus™ Cream

NEWTOWN, PA-April 14th, 2009 - Quinnova Pharmaceuticals, Inc. announced that it has received FDA clearance on the company’s new product NEOSALUS CREAM, a line extension to the previously launched NEOSALUS FOAM, the first non-steroidal anti-inflammatory prescription topical foam product…
March 17, 2009 - HyperBranch Medical Technology, Inc Licenses OcuSeal Liquid Ocular Bandage to BD Medical-Ophthalmic Systems

Durham, NC - 03/17/2009 - HyperBranch Medical Technology, Inc., announced today the licensing of the Company's OcuSeal Liquid Ocular Bandage to BD Medical Ophthalmic Systems. OcuSeal is a fully synthetic ocular bandage designed as a temporary protective barrier to provide comfort for…
August 6, 2008 - Quinnova Pharmaceuticals, Inc. Launches Cleanse and Treat

NEWTOWN, PA-August 6, 2008-Quinnova Pharmaceuticals, Inc. announced today the commercial launch of Cleanse and Treat. Cleanse and Treat is the first prescription acne medication with a two-sided pad system (One + One Technology). One side of the pad…
May 8, 2007 - Zilker Labs’ Digital-DC Technology Drives Ericsson Digital Power Study

AUSTIN, Texas - May 8, 2007 - Zilker Labs, Inc., today announced that its ZL2005 digital power conversion and management IC is featured in two experimental digital power module designs to support a case study presented by Ericsson Power Modules, a unit of Ericsson (NASDAQ: ERIC), at…
November 28, 2006 - Quinnova Pharmaceuticals, Inc. Completes $13.6 Million Series A Financing

NEWTOWN, P.A. - November 28, 2006 - Quinnova Pharmaceuticals, Inc., a specialty dermatological pharmaceutical company focused on the development and commercial sale of prescription drug products based on innovative dermal drug delivery platforms, announced today that it has completed…
August 10, 2006 - Tranzyme Pharma Appoints New Vice President of Business Development & Licensing

RESEARCH TRIANGLE PARK, N.C. and SHERBROOKE, Québec - August 10, 2006 -Tranzyme Pharma, a leading biopharmaceutical company developing novel small molecule therapeutics for the treatment of gastrointestinal (GI) and metabolic diseases, announced today the appointment…
July 11, 2006 - Alder Biopharmaceuticals Inc. Completes Series B Financing

Bothell, Washington, - July 11, 2006 -- Alder Biopharmaceuticals Inc., an emerging antibody therapeutics company, today announced the closing of its Series B financing. H.I.G. Ventures led the $16 million round and was joined by existing investors Sevin Rosen Funds, Ventures West, and…
April 24, 2006 - CardioFocus Completes Series C Financing

BOSTON, MASS - April 24, 2006 - CardioFocus, Inc., a privately held company focused on developing and commercializing catheter products for the treatment of atrial fibrillation (AFib), announced today it has raised a $21.5 million Series C round to propel the performance of a U.S. pivotal…